[go: up one dir, main page]

WO2020015698A1 - 一种凝血因子XIa抑制剂及其中间体的制备方法 - Google Patents

一种凝血因子XIa抑制剂及其中间体的制备方法 Download PDF

Info

Publication number
WO2020015698A1
WO2020015698A1 PCT/CN2019/096504 CN2019096504W WO2020015698A1 WO 2020015698 A1 WO2020015698 A1 WO 2020015698A1 CN 2019096504 W CN2019096504 W CN 2019096504W WO 2020015698 A1 WO2020015698 A1 WO 2020015698A1
Authority
WO
WIPO (PCT)
Prior art keywords
group
compound represented
hydrogen atom
formula
substituted
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/CN2019/096504
Other languages
English (en)
French (fr)
Inventor
奚倬勋
冯莹强
冯君
贺峰
黄建
毛彦利
王勇
管忠俊
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Jiangsu Hengrui Medicine Co Ltd
Shanghai Hengrui Pharmaceutical Co Ltd
Original Assignee
Jiangsu Hengrui Medicine Co Ltd
Shanghai Hengrui Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to JP2021500812A priority Critical patent/JP2021530497A/ja
Priority to CN201980004506.0A priority patent/CN111094268B/zh
Priority to BR112021000439-4A priority patent/BR112021000439A2/pt
Priority to KR1020207037803A priority patent/KR20210033953A/ko
Priority to AU2019304392A priority patent/AU2019304392A1/en
Priority to EP19837834.1A priority patent/EP3825311A4/en
Priority to MX2021000256A priority patent/MX2021000256A/es
Priority to CA3106120A priority patent/CA3106120A1/en
Priority to US17/259,917 priority patent/US20210292279A1/en
Application filed by Jiangsu Hengrui Medicine Co Ltd, Shanghai Hengrui Pharmaceutical Co Ltd filed Critical Jiangsu Hengrui Medicine Co Ltd
Publication of WO2020015698A1 publication Critical patent/WO2020015698A1/zh
Priority to ZA2020/07755A priority patent/ZA202007755B/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62—Oxygen or sulfur atoms
    • C07D213/69—Two or more oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4418—Non condensed pyridines; Hydrogenated derivatives thereof having a carbocyclic group directly attached to the heterocyclic ring, e.g. cyproheptadine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
    • C07C235/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton
    • C07C235/32—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton containing six-membered aromatic rings
    • C07C235/38—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton containing six-membered aromatic rings having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
    • C07C309/63—Esters of sulfonic acids
    • C07C309/64—Esters of sulfonic acids having sulfur atoms of esterified sulfo groups bound to acyclic carbon atoms
    • C07C309/65—Esters of sulfonic acids having sulfur atoms of esterified sulfo groups bound to acyclic carbon atoms of a saturated carbon skeleton
    • C07C309/66—Methanesulfonates
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
    • C07C309/63—Esters of sulfonic acids
    • C07C309/72—Esters of sulfonic acids having sulfur atoms of esterified sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
    • C07C309/73—Esters of sulfonic acids having sulfur atoms of esterified sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton to carbon atoms of non-condensed six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/07—Optical isomers

Definitions

  • the present disclosure belongs to the field of medicine and relates to a method for preparing a coagulation factor XIa inhibitor.
  • the human blood coagulation process is composed of an intrinsic pathway, an external pathway and a common pathway. It is a chain reaction in which processes are continuously strengthened and amplified by multiple zymogens being activated sequentially.
  • the coagulation cascade is initiated by the endogenous pathway (also known as the contact activation pathway) and the exogenous pathway (also known as the tissue factor pathway) to produce FXa, and then through the common pathway to generate thrombin (FIIa), and finally forms fibrin.
  • the endogenous pathway refers to the process by which factor XII is activated to form the XIa-VIIIa-Ca2 ⁇ P complex and activate factor X.
  • the exogenous coagulation pathway is the release of tissue factor (TF) to the TF-VIIaCa2 + complex.
  • the process of forming and activating factor X refers to the process in which the two pathways merge into one after the formation of factor Xa, which activates prothrombin and finally generates fibrin.
  • FXI is necessary to maintain the endogenous pathway, and during the amplification of the coagulation cascade Play a key role.
  • FXIa activated FXI
  • FXI antagonists have been widely developed for the treatment of various thrombosis.
  • WO2018041122 discloses a class of effective FXIa inhibitors and preparation methods thereof. Among them, the compound represented by Formula I and the compound represented by Formula VI have obvious medicinal effects. In the existing preparation method, a racemate is first prepared and then resolved to obtain a target compound.
  • An object of the present disclosure is to provide a new method for preparing a factor XIa inhibitor.
  • a method for preparing a compound represented by Formula AI includes a step of reacting a compound represented by Formula III with a compound represented by Formula II.
  • Ring A is aryl or heteroaryl
  • R 1 is the same or different, and each is independently selected from a hydrogen atom, halogen, alkyl, haloalkyl, alkoxy, haloalkoxy, amino, nitro, cyano, hydroxyl, hydroxyalkyl, -C (O ) R 5 , cycloalkyl, heterocyclyl, aryl and heteroaryl;
  • R 2 is selected from the group consisting of halogen, alkyl, haloalkyl, alkoxy, cycloalkyloxy, haloalkoxy, amino, nitro, cyano, hydroxy, hydroxyalkyl, and alkylthio, wherein said alkyl , Alkoxy, haloalkyl, haloalkoxy, hydroxyalkyl and alkylthio are optionally further selected from the group consisting of deuterium, halogen, alkoxy, haloalkoxy, amino, nitro, cyano, hydroxy, and hydroxyalkane With one or more substituents in the group;
  • L 1 is an alkylene group, wherein the alkylene group is optionally further substituted with one or more substituents in a halogen or deuterium atom;
  • R 3 is the same or different, and each is independently selected from the group consisting of a hydrogen atom, an alkyl group, an alkoxy group, an oxo group, a halogen, a haloalkyl group, a haloalkoxy group, an amino group, a nitro group, a cyano group, a hydroxy group, a hydroxyalkyl group, a cyclic group Alkyl, heterocyclyl, aryl, heteroaryl, -C (O) R 6 , -C (O) OR 6 , -NHC (O) R 6 , -NHC (O) OR 6 , -NR 7 R 8 , -C (O) NR 7 R 8 , -CH 2 NHC (O) OR 6 , -CH 2 NR 7 R 8 , -C (O) OCH (R 7 ) R 8 and -S (O) m R 6 , wherein the alkyl group is optionally further selected from the
  • R 4 is selected from a hydrogen atom, a deuterium atom, a halogen, an alkyl group, an alkoxy group, an amino group, a nitro group, a cyano group, a hydroxy group, a hydroxyalkyl group, a cycloalkyl group, a cycloalkyloxy group, a heterocyclic group, an aryl group, and Heteroaryl, wherein said cycloalkyl, heterocyclyl, aryl and heteroaryl are optionally further selected from deuterium, halogen, alkyl, alkoxy, haloalkyl, amino, nitro, cyano , Hydroxy, hydroxyalkyl, cycloalkyl, cycloalkyloxy, heterocyclyl, -NHC (O) R 9 and R 10 are substituted with one or more substituents;
  • R 5 is selected from the group consisting of a hydrogen atom, an alkyl group, a haloalkyl group, an alkoxy group, a haloalkoxy group, an amino group, a hydroxy group, a hydroxyalkyl group, a cycloalkyl group, a heterocyclic group, an aryl group, and a heteroaryl group, wherein the alkyl group , Alkoxy, cycloalkyl, heterocyclyl, aryl, and heteroaryl are optionally further selected from the group consisting of hydrogen atom, deuterium atom, halogen, alkyl, alkoxy, haloalkoxy, amino, nitro, cyano Substituted with one or more substituents of hydroxy, hydroxy, hydroxyalkyl, cycloalkyl, cycloalkyloxy, heterocyclyl, aryl, and heteroaryl;
  • R 6 is selected from a hydrogen atom, an alkyl group, a haloalkyl group, a hydroxyl group, an amino group, a cycloalkyl group, a heterocyclic group, an aryl group, a heteroaryl group, and a carboxy protecting group;
  • R 7 and R 8 are the same or different and are each independently selected from a hydrogen atom, an alkyl group, a haloalkyl group, a cycloalkyl group, a heterocyclic group, -C (O) OR 6 and -OC (O) OR 9 , wherein The cycloalkyl and heterocyclyl are optionally further selected from one of a deuterium atom, a halogen, an alkyl group, an alkoxy group, a haloalkyl group, an oxo group, an amino group, a nitro group, a cyano group, a hydroxy group, and a hydroxyalkyl group. Or more than one substituent;
  • R 9 is selected from a hydrogen atom, an alkyl group, an alkoxy group, a haloalkyl group, a haloalkoxy group, an amino group, a cycloalkyl group, a heterocyclic group, an aryl group, and a heteroaryl group;
  • R 10 is aryl or heteroaryl, wherein the aryl and heteroaryl are optionally further selected from hydrogen atom, deuterium atom, halogen, alkyl, alkoxy, haloalkyl, amino, nitro, cyano Substituted with one or more substituents of the group, hydroxy, hydroxyalkyl, cycloalkyl, cycloalkyloxy and heterocyclic group;
  • LG is a leaving group, preferably halogen, substituted sulfonyloxy, R i R j N-, hydroxyl, cyano, R k S-, substituted or unsubstituted phosphoryloxy, substituted formyloxy
  • R i and R j are independently selected from a hydrogen atom, a C 1 to C 6 alkyl group or an amino protecting group
  • R k is selected from a hydrogen atom and a C 1 to C 6 alkyl group
  • n 0, 1, 2, 3, or 4;
  • n 0, 1, or 2;
  • s 0, 1, 2, 3, or 4.
  • the compound represented by Formula III is reacted with a compound represented by Formula II in the presence of a basic substance.
  • the basic substance may be Na 2 CO 3 , K 2 CO 3 , Cs 2 CO 3 , NaHCO 3 , KHCO 3 , Na 2 HPO 4 , K 2 HPO 4 , K 3 PO 4 , Na 3 PO 4 , LiHMDS, NaHMDS, KHMDS, Ba (OH) 2 , LiOR a , NaOR a , KOR a , CsOR a , TlOR a , NR b R c R d , DBU, DBN, Mg (OR a ) 2 , LiR e , NaNH 2 , KNH One or more of 2 , LiNH 2 , LiH, NaH, KH, CaH 2 , MgH 2 , R f MgX, KF, CsF, Bu 4 F, quaternary ammonium salt, wherein R a is independently selected from a hydrogen atom or C 1 to C 6 alkyl, R b, R c , and R d are each independently
  • the basic substance is preferably tBuOK, LiHMDS, NaHMDS, KHMDS, LiH, NaH, KH, CaH 2 , One or more of MgH 2 , TBAI, TBAF, TBAB, TBAC, Na 2 CO 3 , K 2 CO 3 , Cs 2 CO 3 , K 3 PO 4 , and Na 3 PO 4 .
  • the solvent used in the reaction may be a conventional solvent, such as water, dimethylformamide, 1-methyl-2-pyrrolidone, tetrahydrofuran, methyltetrahydrofuran, dioxane, toluene, xylene, dimethylsulfoxide, One or more of diethyl ether, isopropyl ether, methyl tert-butyl ether, acetonitrile, propionitrile, C 1 to C 6 alkyl alcohol, acetone, and ethyl acetate.
  • a conventional solvent such as water, dimethylformamide, 1-methyl-2-pyrrolidone, tetrahydrofuran, methyltetrahydrofuran, dioxane, toluene, xylene, dimethylsulfoxide, One or more of diethyl ether, isopropyl ether, methyl tert-butyl ether, acetonitrile, propionitrile, C
  • the reaction temperature of the reaction may be -20 ° C to 100 ° C, preferably -20 ° C to 60 ° C, and more preferably -10 ° C to 40 ° C.
  • the molar ratio of the compound represented by Formula II to the basic substance may be 1: 1 to 1:20, preferably 1: 1 to 1: 8.
  • the substituted sulfonyloxy group may be a C 1 to C 6 alkylsulfonyloxy group, a perfluoro C 1 to C 6 alkylsulfonyloxy group, an arylsulfonyloxy group, Aralkylsulfonyloxy, heteroarylsulfonyloxy.
  • C 1 ⁇ C 6 alkyl sulfonyl group examples include C 1 ⁇ C 6 linear or branched alkylsulfonyl groups such as methylsulfonyl group, ethylsulfonyl group, n-propyl Sulfonyloxy, isopropylsulfonyloxy, n-butylsulfonyloxy, t-butylsulfonyloxy, n-pentylsulfonyloxy, and n-hexylsulfonyloxy.
  • C 1 ⁇ C 6 alkyl sulfonyl group examples include C 1 ⁇ C 6 linear or branched alkylsulfonyl groups such as methylsulfonyl group, ethylsulfonyl group, n-propyl Sulfonyloxy, isopropylsulfonyloxy, n-butylsulf
  • perfluoroC 1 to C 6 alkylsulfonyloxy include C 1 to C 6 straight or branched chain perfluoroalkylsulfonyloxy, such as trifluoromethylsulfonyloxy, 1,1 , 2,2,2-pentafluoro-1-ethylsulfonyloxy, 1,1,2,2,3,3,3-heptafluoro-1-propylsulfonyloxy and 1,1,2 , 2,3,3,4,4,4-nonafluoro-1-butylsulfonyloxy.
  • arylsulfonyloxy group examples include: optionally having 1 to 3 alkyl groups on the benzene ring selected from C 1 to C 6 straight or branched alkyl, C 1 to C 6 straight or branched alkyl Phenylsulfonyloxy and naphthylsulfonyloxy which are substituents of the group consisting of nitro, nitro and halogen atoms.
  • phenylsulfonyloxy group optionally having a substituent include phenylsulfonyloxy, 4-methylphenylsulfonyloxy, 2-methylphenylsulfonyloxy, 4-nitro Phenylsulfonyloxy, 4-tolylsulfonyloxy, 2-nitrophenylsulfonyloxy, 3-chlorophenylsulfonyloxy, and the like.
  • naphthylsulfonyloxy include ⁇ -naphthylsulfonyloxy, ⁇ -naphthylsulfonyloxy, and the like.
  • aralkylsulfonyloxy examples include: phenyl (which optionally has 1 to 3 alkyl groups selected from C 1 to C 6 straight or branched on the benzene ring, C 1 to C 6 straight Chain or branched alkane, nitro, and halogen atom substituents) substituted C 1 to C 6 straight or branched alkylsulfonyloxy; and C 1 to C 6 substituted with naphthyl or Branched alkylsulfonyloxy.
  • alkylsulfonyloxy substituted with phenyl include benzylsulfonyloxy, 2-phenylethylsulfonyloxy, 4-phenylbutylsulfonyloxy, 4-methylbenzyl Sulfonyloxy, 2-methylbenzylsulfonyloxy, 4-nitrobenzylsulfonyloxy, 4-methylbenzylsulfonyloxy, 3-chlorobenzylsulfonyloxy, and the like.
  • alkylsulfonyloxy group substituted with a naphthyl group examples include ⁇ -naphthylmethylsulfonyloxy, ⁇ -naphthylmethylsulfonyloxy, and the like.
  • Examples of the substituted phosphoryloxy group and the substituted formyloxy group are basically the same as those of the substituted sulfonyloxy group.
  • the leaving group may be p-toluenesulfonyloxy, trifluoromethanesulfonyloxy, methanesulfonyloxy, p-nitrobenzenesulfonyloxy, and the like.
  • the compound represented by Formula II is a compound represented by Formula IIa,
  • L 1 , R 3 , R 4 , and LG are as described above.
  • the compound represented by Formula II is a compound represented by Formula IIb,
  • LG is a leaving group, preferably halogen, substituted sulfonyloxy, R i R j N-, hydroxyl, cyano, R k S-, substituted or unsubstituted phosphoryloxy, substituted formyl
  • An oxygen group wherein R i and R j are independently selected from a hydrogen atom, a C 1 to C 6 alkyl group or an amino protecting group, and R k is selected from a hydrogen atom and a C 1 to C 6 alkyl group;
  • halogen C 1 to C 6 alkylsulfonyloxy, perfluoro C 1 to C 6 alkylsulfonyloxy, arylsulfonyloxy, aralkylsulfonyloxy, heteroarylsulfonyl Oxy, R i R j N-, hydroxy, cyano, R k S-, substituted or unsubstituted phosphoryloxy, substituted formyloxy;
  • Y is selected from a hydrogen atom and a carboxy protecting group, and is preferably a hydrogen atom, a methyl group, an ethyl group, an allyl group, an isopentenyl group, and a trimethylsilylethyl group.
  • the compound represented by Formula II is a compound represented by Formula IIc,
  • LG is a leaving group, preferably halogen, substituted sulfonyloxy, R i R j N-, hydroxy, R k S-, substituted or unsubstituted phosphoryloxy, substituted formyloxy,
  • R i and R j are independently selected from a hydrogen atom, a C 1 to C 6 alkyl group, or an amino protecting group
  • R k is selected from a hydrogen atom and a C 1 to C 6 alkyl group
  • halogen C 1 to C 6 alkylsulfonyloxy, perfluoro C 1 to C 6 alkylsulfonyloxy, arylsulfonyloxy, aralkylsulfonyloxy, heteroarylsulfonyl Oxy, R i R j N-, hydroxy, R k S-, substituted or unsubstituted phosphoryloxy, substituted formyloxy;
  • Y is selected from a hydrogen atom and a carboxy protecting group, and is preferably a hydrogen atom, a methyl group, an ethyl group, an allyl group, an isopentenyl group, and a trimethylsilylethyl group.
  • the compound represented by Formula III is a compound represented by Formula IIIa,
  • R 1 is the same or different, and each is independently selected from a hydrogen atom, halogen, alkyl, haloalkyl, alkoxy, haloalkoxy, amino, nitro, cyano, hydroxy, hydroxyalkyl, and cycloalkyl , Heterocyclyl, aryl and heteroaryl;
  • R 5 is selected from the group consisting of alkyl, cycloalkyl and haloalkyl, wherein said alkyl or cycloalkyl is optionally further substituted by one or more substituents selected from deuterium, halogen, alkyl and cycloalkyl Replace
  • R 2 and n are as described above.
  • the compound represented by Formula III is a compound represented by Formula IIIb,
  • the compound represented by Formula III is a compound represented by Formula IIIc,
  • the preparation method further includes a step of reacting a compound represented by Formula IV with a compound represented by Formula V to prepare a compound represented by Formula II,
  • R 11 is selected from -OR 9 and halogen
  • LG ' is the same as or different from LG and is selected from halogen, substituted sulfonyloxy, R i R j N-, hydroxyl, R k S-, substituted or unsubstituted phosphoryloxy, substituted formyloxy,
  • R i and R j are independently selected from a hydrogen atom, a C 1 to C 6 alkyl group, or an amino protecting group
  • R k is selected from a hydrogen atom and a C 1 to C 6 alkyl group
  • L 1 , R 3 , R 4 , R 9 , LG, and s are as described above.
  • Another aspect of the present disclosure provides a compound represented by Formula IIb,
  • LG is a leaving group, preferably halogen, substituted sulfonyloxy, R i R j N-, hydroxyl, cyano, R k S-, substituted formyloxy, wherein R i and R j are independent Ground is selected from a hydrogen atom, a C 1 to C 6 alkyl group or an amino protecting group, and R k is selected from a hydrogen atom, a C 1 to C 6 alkyl group;
  • halogen C 1 to C 6 alkylsulfonyloxy, perfluoro C 1 to C 6 alkylsulfonyloxy, arylsulfonyloxy, aralkylsulfonyloxy, heteroarylsulfonyl Oxy, R i R j N-, hydroxy, cyano, R k S-, substituted formyloxy;
  • Y is selected from a hydrogen atom and a carboxy protecting group, preferably a hydrogen atom, a methyl group, an ethyl group, an allyl group, an isopentenyl group, and a trimethylsilylethyl group;
  • LG is a hydroxyl group
  • Y is not a methyl group
  • Another aspect of the present disclosure provides a method for preparing a compound represented by Formula IIb, comprising a step of reacting a compound represented by Formula IVb or a salt thereof with a compound represented by Formula Vb or a salt thereof,
  • R 11 is selected from -OR 9 and halogen;
  • R 9 is selected from hydrogen atom, alkyl, alkoxy, haloalkyl, haloalkoxy, amino, cycloalkyl, heterocyclyl, aryl, and heteroaryl;
  • LG ' is the same as or different from LG and is selected from halogen, substituted sulfonyloxy, R i R j N-, hydroxyl, R k S-, substituted or unsubstituted phosphoryloxy, substituted formyloxy,
  • R i and R j are independently selected from a hydrogen atom, a C 1 to C 6 alkyl group or an amino protecting group
  • R k is selected from a hydrogen atom and a C 1 to C 6 alkyl group; the definitions of LG and Y are shown in formula IIb As defined in the compound.
  • the salt of the compound represented by Formula IVb may be a sodium salt, a potassium salt, an amine salt, and the like.
  • the salt of the compound represented by Formula Vb may be a hydrochloride, a sulfate, a phosphate, an acetate, or the like.
  • Another aspect of the present disclosure provides a compound represented by Formula IIc,
  • LG is a leaving group, preferably halogen, substituted sulfonyloxy, R i R j N-, hydroxy, R k S-, substituted or unsubstituted phosphoryloxy, substituted formyloxy,
  • R i and R j are independently selected from a hydrogen atom, a C 1 to C 6 alkyl group, or an amino protecting group
  • R k is selected from a hydrogen atom and a C 1 to C 6 alkyl group
  • halogen C 1 to C 6 alkylsulfonyloxy, perfluoro C 1 to C 6 alkylsulfonyloxy, arylsulfonyloxy, aralkylsulfonyloxy, heteroarylsulfonyl Oxy, R i R j N-, hydroxy, R k S-, substituted formyloxy;
  • Y is selected from a hydrogen atom and a carboxy protecting group, and is preferably a hydrogen atom, a methyl group, an ethyl group, an allyl group, an isopentenyl group, and a trimethylsilylethyl group.
  • Another aspect of the present disclosure provides a method for preparing a compound represented by Formula IIc, comprising a step of reacting a compound represented by Formula IVc or a salt thereof with a compound represented by Formula Vb or a salt thereof,
  • R 11 is selected from -OR 9 and halogen;
  • R 9 is selected from hydrogen atom, alkyl, alkoxy, haloalkyl, haloalkoxy, amino, cycloalkyl, heterocyclyl, aryl, and heteroaryl;
  • LG ' is the same as or different from LG and is selected from halogen, substituted sulfonyloxy, R i R j N-, hydroxyl, R k S-, substituted or unsubstituted phosphoryloxy, substituted formyloxy,
  • R i and R j are independently selected from a hydrogen atom, a C 1 to C 6 alkyl group or an amino protecting group
  • R k is selected from a hydrogen atom and a C 1 to C 6 alkyl group; the definitions of LG and Y are shown in formula IIc As defined in the compound.
  • the salt of the compound represented by Formula IVc may be a sodium salt, a potassium salt, an amine salt, or the like.
  • the salt of the compound represented by Formula Vb may be a hydrochloride, a sulfate, a phosphate, an acetate, or the like.
  • Another aspect of the present disclosure also provides a compound represented by Formula IVd,
  • Y1 is selected from a hydrogen atom or a carboxy protecting group
  • Y2 is selected from a hydrogen atom or a hydroxy protecting group.
  • Another aspect of the present disclosure also provides a method for preparing a compound represented by Formula IVd, including a step of converting a compound represented by Formula IVe into a compound represented by Formula IVd,
  • Another aspect of the present disclosure also provides a method for preparing a compound represented by Formula I or a pharmaceutically acceptable salt thereof, comprising a step of reacting a compound represented by Formula IIIb with a compound represented by Formula IIb to prepare a compound represented by Formula BI, Among them, the definitions of LG and Y are as described above.
  • the compound represented by Formula IIIb and the compound represented by Formula IIb are reacted in the presence of a basic substance.
  • the basic substance may be Na 2 CO 3 , K 2 CO 3 , Cs 2 CO 3 , NaHCO 3 , KHCO 3 , Na 2 HPO 4 , K 2 HPO 4 , K 3 PO 4 , Na 3 PO 4 , LiHMDS, NaHMDS, KHMDS, Ba (OH) 2 , LiOR a , NaOR a , KOR a , CsOR a , TlOR a , NR b R c R d , DBU, DBN, Mg (OR a ) 2 , LiR e , NaNH 2 , KNH One or more of 2 , LiNH 2 , LiH, NaH, KH, CaH 2 , MgH 2 , R f MgX, KF, CsF, Bu 4 F, quaternary ammonium salt, wherein R a is independently selected from a hydrogen atom or C 1 to C 6 alkyl, R b, R c , and R d are each independently
  • the basic substance is preferably tBuOK, LiHMDS, NaHMDS, KHMDS, LiH, NaH, KH, CaH 2 , MgH 2 , TBAI, TBAF, TBAB, TBAC, Na 2 CO 3 , K 2 CO 3 , Cs 2 CO 3 , K 3 PO 4 , Na 3 PO 4 .
  • the solvent used in the reaction may be a conventional solvent, such as water, dimethylformamide, 1-methyl-2-pyrrolidone, tetrahydrofuran, methyltetrahydrofuran, dioxane, toluene, xylene, dimethylsulfoxide, One or more of diethyl ether, isopropyl ether, methyl tert-butyl ether, acetonitrile, propionitrile, C 1 to C 6 alkyl alcohol, acetone, and ethyl acetate.
  • a conventional solvent such as water, dimethylformamide, 1-methyl-2-pyrrolidone, tetrahydrofuran, methyltetrahydrofuran, dioxane, toluene, xylene, dimethylsulfoxide, One or more of diethyl ether, isopropyl ether, methyl tert-butyl ether, acetonitrile, propionitrile, C
  • the reaction temperature of the reaction may be -20 ° C to 100 ° C, preferably -20 ° C to 60 ° C, and more preferably -10 ° C to 40 ° C.
  • the molar ratio of the compound represented by Formula IIb to the basic substance may be 1: 1 to 1:20, preferably 1: 1 to 1: 8.
  • the method may further include a step of preparing a compound represented by Formula IIb according to the present disclosure.
  • LG is selected from substituted sulfonyloxy groups, and the method further comprises the step of converting a compound represented by formula IIcIId into a compound represented by formula IIb,
  • the compound represented by Formula IIcIId can be prepared by a method for preparing a compound represented by Formula II according to the present disclosure.
  • the method may further include a step of decarboxy protecting the compound represented by Formula BI.
  • Another aspect of the present disclosure also provides a method for preparing a compound represented by Formula VI or a pharmaceutically acceptable salt thereof, comprising a step of reacting a compound represented by Formula IIIc with a compound represented by Formula IIc to prepare a compound represented by Formula BVI, wherein
  • the definitions of LG and Y are as described above,
  • the compound represented by Formula IIIc and the compound represented by Formula IIc are reacted in the presence of a basic substance.
  • the basic substance may be Na 2 CO 3 , K 2 CO 3 , Cs 2 CO 3 , NaHCO 3 , KHCO 3 , Na 2 HPO 4 , K 2 HPO 4 , K 3 PO 4 , Na 3 PO 4 , LiHMDS, NaHMDS, KHMDS, Ba (OH) 2 , LiOR a , NaOR a , KOR a , CsOR a , TlOR a , NR b R c R d , DBU, DBN, Mg (OR a ) 2 , LiR e , NaNH 2 , KNH One or more of 2 , LiNH 2 , LiH, NaH, KH, CaH 2 , MgH 2 , R f MgX, KF, CsF, Bu 4 F, quaternary ammonium salt, wherein R a is independently selected from a hydrogen atom or C 1 to C 6 alkyl, R b, R c , and R d are each independently
  • the basic substance is preferably tBuOK, LiHMDS, NaHMDS, KHMDS, LiH, NaH, KH, CaH 2 , MgH 2 , TBAI, TBAF, TBAB, TBAC, Na 2 CO 3 , K 2 CO 3 , Cs 2 CO 3 , K 3 PO 4 , Na 3 PO 4 .
  • the solvent used in the reaction may be a conventional solvent, such as water, dimethylformamide, 1-methyl-2-pyrrolidone, tetrahydrofuran, methyltetrahydrofuran, dioxane, toluene, xylene, dimethylsulfoxide, One or more of diethyl ether, isopropyl ether, methyl tert-butyl ether, acetonitrile, propionitrile, C 1 to C 6 alkyl alcohol, acetone, and ethyl acetate.
  • a conventional solvent such as water, dimethylformamide, 1-methyl-2-pyrrolidone, tetrahydrofuran, methyltetrahydrofuran, dioxane, toluene, xylene, dimethylsulfoxide, One or more of diethyl ether, isopropyl ether, methyl tert-butyl ether, acetonitrile, propionitrile, C
  • the reaction temperature of the reaction may be -20 ° C to 100 ° C, preferably -20 ° C to 60 ° C, and more preferably -10 ° C to 40 ° C.
  • the molar ratio of the compound represented by Formula IIc to the basic substance may be 1: 1 to 1:20, preferably 1: 1 to 1: 8.
  • the method may further include a step of preparing a compound represented by Formula IIc according to the present disclosure.
  • LG is selected from substituted sulfonyloxy groups, and the method further comprises the step of converting a compound represented by Formula IIe into a compound represented by Formula IIc,
  • the compound represented by Formula IIe can be prepared by a method for preparing a compound represented by Formula II according to the present disclosure.
  • the method may further include the step of decarboxylating the compound of formula BVI.
  • the preparation method of the FXIa inhibitor and the intermediate thereof according to the present disclosure directly synthesizes a stereoisomeric target product through a chiral synthesis method without resolving a racemate.
  • the optical purity of the product during the entire reaction process is maintained, and the reaction yield is greatly improved, which is conducive to industrial production.
  • alkyl refers to a saturated aliphatic hydrocarbon group, which is a straight or branched chain group containing 1 to 20 carbon atoms, preferably an alkyl group containing 1 to 12 carbon atoms.
  • Non-limiting examples include methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, tert-butyl, sec-butyl, n-pentyl, 1,1-dimethylpropyl, 1 2,2-dimethylpropyl, 2,2-dimethylpropyl, 1-ethylpropyl, 2-methylbutyl, 3-methylbutyl, n-hexyl, 1-ethyl-2- Methylpropyl, 1,1,2-trimethylpropyl, 1,1-dimethylbutyl, 1,2-dimethylbutyl, 2,2-dimethylbutyl, 1,3 -Dimethylbutyl, 2-ethylbutyl, 2-methylpent
  • lower alkyl groups containing 1 to 6 carbon atoms include methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, tert-butyl, sec-butyl Methyl, n-pentyl, 1,1-dimethylpropyl, 1,2-dimethylpropyl, 2,2-dimethylpropyl, 1-ethylpropyl, 2-methylbutyl, 3-methylbutyl, n-hexyl, 1-ethyl-2-methylpropyl, 1,1,2-trimethylpropyl, 1,1-dimethylbutyl, 1,2-dimethyl Butylbutyl, 2,2-dimethylbutyl, 1,3-dimethylbutyl, 2-ethylbutyl, 2-methylpentyl, 3-methylpentyl, 4-methylpentyl Group, 2,3-dimethylbutyl and the like.
  • the alkyl group may be substituted or unsubstituted. When substituted, the substituent may be substituted at any available point of attachment.
  • the substituent is preferably one or more of the following groups, which are independently selected from alkane Alkyl, alkenyl, alkynyl, alkoxy, alkylthio, alkylamino, halogen, mercapto, hydroxyl, nitro, cyano, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, cycloalkane Oxy, heterocycloalkoxy, cycloalkylthio, heterocycloalkylthio, oxo, carboxyl or carboxylate.
  • alkylene refers to a saturated straight or branched chain aliphatic hydrocarbon group having 2 residues derived from the same carbon atom or two different carbon atoms of the parent alkane, which is derived from A straight or branched chain group containing 1 to 20 carbon atoms, preferably an alkylene group containing 1 to 12 carbon atoms, and more preferably 1 to 6 carbon atoms.
  • Non-limiting examples of alkylene include, but are not limited to, methylene (-CH 2- ), 1,1-ethylene (-CH (CH 3 )-), 1,2-ethylene (-CH 2 CH 2 )-, 1,1-propylene (-CH (CH 2 CH 3 )-), 1,2-propylene (-CH 2 CH (CH 3 )-), 1,3-propylene (-CH 2 CH 2 CH 2- ), 1,4-butylene (-CH 2 CH 2 CH 2 CH 2- ), and the like.
  • the alkylene group may be substituted or unsubstituted, and when substituted, the substituent may be substituted at any available point of attachment.
  • cycloalkyl refers to a saturated or partially unsaturated monocyclic or polycyclic cyclic hydrocarbon substituent.
  • the cycloalkyl ring contains 3 to 20 carbon atoms, preferably 3 to 12 carbon atoms, and more preferably 3 to 6 Carbon atoms.
  • Non-limiting examples of monocyclic cycloalkyl include cyclopropyl, cyclobutyl, cyclopentyl, cyclopentenyl, cyclohexyl, cyclohexenyl, cyclohexadienyl, cycloheptyl, cycloheptatriene Groups, cyclooctyl and the like; polycyclic cycloalkyl groups include spiro, fused and bridged cycloalkyl.
  • heterocyclyl refers to a saturated or partially unsaturated monocyclic or polycyclic cyclic hydrocarbon substituent that contains 3 to 20 ring atoms, one or more of which are selected from nitrogen, oxygen, or S (O) A heteroatom of m (where m is an integer from 0 to 2), excluding the ring portion of -OO-, -OS-, or -SS-, and the remaining ring atoms are carbon. It preferably contains 3 to 12 ring atoms, of which 1 to 4 are heteroatoms; more preferably 3 to 6 ring atoms.
  • Non-limiting examples of monocyclic heterocyclyl include pyrrolidinyl, imidazolidinyl, tetrahydrofuryl, tetrahydrothienyl, dihydroimidazolyl, dihydrofuryl, dihydropyrazolyl, dihydropyrrolyl, piperidine Group, piperazinyl, morpholinyl, thiomorpholinyl, homopiperazinyl, and the like, piperidinyl and pyrrolidinyl are preferred.
  • Polycyclic heterocyclic groups include spiro, fused and bridged heterocyclic groups.
  • aryl refers to a 6 to 14 membered, all-carbon monocyclic or fused polycyclic (ie, rings that share adjacent pairs of carbon atoms) group having a conjugated pi-electron system, preferably 6 to 10 members, such as benzene And naphthyl.
  • the aryl ring may be fused to a heteroaryl, heterocyclic or cycloalkyl ring, wherein the ring connected to the parent structure is an aryl ring, and non-limiting examples thereof include:
  • an aryl group may be substituted or unsubstituted.
  • the substituent is preferably one or more of the following groups, which are independently selected from alkyl, alkenyl, alkynyl, alkoxy, alkylthio, Alkylamino, halogen, mercapto, hydroxyl, nitro, cyano, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, cycloalkoxy, heterocycloalkoxy, cycloalkylthio, heterocycle Alkylthio, carboxyl or carboxylate, preferably phenyl.
  • heteroaryl refers to a heteroaromatic system containing 1 to 4 heteroatoms, 5 to 14 ring atoms, wherein the heteroatoms are selected from oxygen, sulfur, and nitrogen.
  • Heteroaryl is preferably 5- to 12-membered, such as imidazolyl, furyl, thienyl, thiazolyl, pyrazolyl, oxazolyl, pyrrolyl, tetrazolyl, pyridyl, pyrimidinyl, thiadiazole, pyrazine Is preferably imidazolyl, pyrazolyl, pyrimidinyl or thiazolyl; more preferably pyrazolyl or thiazolyl.
  • the heteroaryl ring may be fused to an aryl, heterocyclic or cycloalkyl ring, wherein the ring connected to the parent structure is a heteroaryl ring, and non-limiting examples thereof include:
  • Heteroaryl may be optionally substituted or unsubstituted.
  • the substituent is preferably one or more of the following groups independently selected from alkyl, alkenyl, alkynyl, alkoxy, alkane Thio, alkylamino, halogen, mercapto, hydroxyl, nitro, cyano, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, cycloalkoxy, heterocycloalkoxy, cycloalkylthio , Heterocycloalkylthio, carboxyl or carboxylate.
  • alkoxy refers to -O- (alkyl) and -O- (unsubstituted cycloalkyl), where alkyl is as defined above.
  • alkoxy include: methoxy, ethoxy, propoxy, butoxy, cyclopropoxy, cyclobutoxy, cyclopentyloxy, cyclohexyloxy.
  • the alkoxy group may be optionally substituted or unsubstituted.
  • the substituent is preferably one or more of the following groups, which are independently selected from the group consisting of alkyl, alkenyl, alkynyl, alkoxy, and alkane Thio, alkylamino, halogen, mercapto, hydroxyl, nitro, cyano, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, cycloalkoxy, heterocycloalkoxy, cycloalkylthio , Heterocycloalkylthio, carboxyl or carboxylate.
  • alkylthio refers to -S- (alkyl) and -S- (unsubstituted cycloalkyl), wherein alkyl is as defined above.
  • alkylthio include: methylthio, ethylthio, propylthio, butylthio, cyclopropylthio, cyclobutylthio, cyclopentylthio, cyclohexylthio.
  • the alkylthio group may be optionally substituted or unsubstituted.
  • the substituent is preferably one or more of the following groups, which are independently selected from the group consisting of alkyl, alkenyl, alkynyl, alkoxy, and alkane Thio, alkylamino, halogen, mercapto, hydroxyl, nitro, cyano, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, cycloalkoxy, heterocycloalkoxy, cycloalkylthio 1, substituted by one or more substituents in the heterocycloalkylthio group.
  • groups which are independently selected from the group consisting of alkyl, alkenyl, alkynyl, alkoxy, and alkane Thio, alkylamino, halogen, mercapto, hydroxyl, nitro, cyano, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, cycloalkoxy, heterocycloalkoxy, cycloalkylthio 1, substituted
  • halogen refers to fluorine, chlorine, bromine or iodine.
  • Carboxy protecting group is a suitable group for carboxy protection known in the art, see the carboxy protecting group in the literature ("Protective Groups in Organic Synthesis", 5 Th Ed. TW Greene & P. GMWuts) as an example,
  • the carboxy protecting group may be a substituted or unsubstituted C 1-10 straight or branched alkyl group, a substituted or unsubstituted C 2-10 straight or branched alkenyl or alkynyl group, Substituted or unsubstituted C 3-8 cyclic alkyl, substituted or unsubstituted C 5-10 aryl or heteroaryl, or (C 1-8 alkyl or aryl) 3 silyl; preferably C A straight or branched alkyl group of 1-6 , more preferably a straight or branched alkyl group of C 1-4 .
  • amino protecting groups are suitable groups for amino protection known in the art, see amino protecting groups in the literature ("Protective Groups in Organic Synthesis", 5 Th. Ed. TW Greene & P. GMWuts), preferably
  • the amino protecting group may be (C 1-10 alkyl or aromatic) acyl, for example: formyl, acetyl, benzoyl, etc .; it may be (C 1-6 alkyl or C 6-10 aromatic Group) sulfonyl; or (C 1-6 alkoxy or C 6-10 aryloxy) carbonyl, Boc or Cbz; or an alkyl group, such as: trityl (Tr), 2, 4-Dimethoxybenzyl (DMB), p-methoxybenzyl (PMB) or benzyl (Bn).
  • the hydroxy protecting group is a suitable group for hydroxyl protection known in the art, see the hydroxyl protecting group in the literature ("Protective Groups in Organic Synthesis", 5 Th Ed. TW Greene & P. GMWuts).
  • the hydroxy protecting group may be (C 1-10 alkyl or aryl) 3 silyl, for example: triethylsilyl, triisopropylsilyl, tert-butyldimethyl Silyl, tert-butyldiphenylsilyl, etc .; may be C 1-10 alkyl or substituted alkyl, preferably alkoxy or aryl substituted alkyl, more preferably C 1-6 alkoxy substituted C 1-6 alkyl or phenyl substituted C 1-6 alkyl, most preferably C 1-4 alkoxy substituted C 1-4 alkyl, for example: methyl, tert-butyl, allyl, benzyl , Methoxy
  • an heterocyclic group optionally substituted with an alkyl group means that the alkyl group may but need not exist, and this description includes a case where the heterocyclic group is substituted with an alkyl group and a case where the heterocyclic group is not substituted with an alkyl group .
  • the bond The configuration is not specified, that is, if there is conformational isomerism in the chemical structure, the bond Can be or Or both with Two configurations.
  • Place compound 2 (532mg, 3mmol), D-phenyllactic acid (compound 3,500mg, 3mmol) and methylboronic acid (18mg, 0.3mmol) in a reaction flask, add 20mL of toluene and 108uL of water, and raise the temperature to 140 ° C. The reaction was separated under reflux.
  • reaction solution was cooled to room temperature, and 100 mL of dichloromethane was added, followed by washing with 0.5 M hydrochloric acid and 1 M sodium bicarbonate solution, drying over anhydrous sodium sulfate, filtering, and concentrating the filtrate under reduced pressure, and using Combiflash (eluent: two The obtained residue was purified by methyl chloride 100%) to obtain a total of 829 mg of Compound 4 in a yield of 84.9%.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)

Abstract

本公开涉及一种凝血因子XIa抑制剂及其中间体的制备方法。具体而言，本公开涉及一种氧代吡啶酰胺类衍生物的制备方法，该方法收率高、产物纯度好、反应条件温和。

Description

一种凝血因子XIa抑制剂及其中间体的制备方法 技术领域
本公开属于医药领域，涉及一种凝血因子XIa抑制剂的制备方法。
背景技术
人体血液凝固过程由内源性途径(intrinsic pathway)、外源性途径(extrinsic pathway)和共同通路组成，是通过多种酶原被顺序激活而过程不断得到加强和放大的一种连锁反应。凝血级联反应由内源性途径(又称接触激活途径)及外源性途径(又称组织因子途径)启动生成FXa，再经共同途径生成凝血酶(FIIa)，最终形成纤维蛋白。
内源性途径是指由XII因子被激活形XIa-VIIIa-Ca2±P L复合物、并激活X因子的过程，外源性凝血途径则是从组织因子(TF)释放到TF-VIIaCa2+复合物形成并激活因子Ⅹ的过程。共同通路是指因子Xa形成后,两条途径合二为一，激活凝血酶原并最终生成纤维蛋白的过程，其中FXI是维持内源性途径所必需的，而且在凝血级联反应放大过程中发挥关键作用。在凝血级联反应中，凝血酶可反馈激活FXI，活化的FXI(FXIa)又促使凝血酶的大量产生，从而使凝血级联反应放大。因此，FXI的拮抗剂被广泛开发，用于各种血栓的治疗。
WO2018041122公开了一类有效的FXIa抑制剂及其制备方法。其中，式I所示化合物以及式VI所示化合物具有明显的药效优势。现有的制备方法为先制备消旋体再拆分得到目标化合物。
Figure PCTCN2019096504-appb-000001
发明内容
本公开的目的在于提供一种新的凝血因子XIa抑制剂的制备方法。
本公开一方面提供了式AI所示化合物的制备方法，包括式III所示化合物与式II所示化合物反应的步骤，
Figure PCTCN2019096504-appb-000002
其中：
环A为芳基或杂芳基；
R 1相同或不同，且各自独立地选自氢原子、卤素、烷基、卤代烷基、烷氧基、卤代烷氧基、氨基、硝基、氰基、羟基、羟烷基、、-C(O)R 5、环烷基、杂环基、芳基和杂芳基；
R 2选自卤素、烷基、卤代烷基、烷氧基、环烷基氧基、卤代烷氧基、氨基、硝基、氰基、羟基、羟烷基和烷硫基，其中所述的烷基、烷氧基、卤代烷基、卤代烷氧基、羟烷基和烷硫基任选进一步被选自氘原子、卤素、烷氧基、卤代烷氧基、氨基、硝基、氰基、羟基和羟烷基中的一个或多个取代基所取代；
L 1为亚烷基，其中所述的亚烷基任选进一步被卤素或氘原子中的一个或多个取代基所取代；
R 3相同或不同，且各自独立地选自氢原子、烷基、烷氧基、氧代基、卤素、卤代烷基、卤代烷氧基、氨基、硝基、氰基、羟基、羟烷基、环烷基、杂环基、芳基、杂芳基、-C(O)R 6、-C(O)OR 6、-NHC(O)R 6、-NHC(O)OR 6、-NR 7R 8、-C(O)NR 7R 8、-CH 2NHC(O)OR 6、-CH 2NR 7R 8、-C(O)OCH(R 7)R 8和-S(O) mR 6，其中所述的烷基任选进一步被选自氘原子、卤素、烷氧基、卤代烷氧基、氨基、硝基、氰基、羟基、羟烷基、-NR 7R 8和-NHC(O)OR 6中的一个或多个取代基所取代；
R 4选自氢原子、氘原子、卤素、烷基、烷氧基、氨基、硝基、氰基、羟基、羟烷基、环烷基、环烷基氧基、杂环基、芳基和杂芳基，其中所述的环烷基、杂环基、芳基和杂芳基任选进一步被选自氘原子、卤素、烷基、烷氧基、卤代烷基、氨基、硝基、氰基、羟基、羟烷基、环烷基、环烷基氧基、杂环基、-NHC(O)R 9和R 10中的一个或多个取代基所取代；
R 5选自氢原子、烷基、卤代烷基、烷氧基、卤代烷氧基、氨基、羟基、羟烷基、环烷基、杂环基、芳基和杂芳基，其中所述的烷基、烷氧基、环烷基、杂环基、芳基和杂芳基任选进一步被选自氢原子、氘原子、卤素、烷基、烷氧基、卤代烷氧基、氨基、硝基、氰基、羟基、羟烷基、环烷基、环烷基氧基、杂环基、芳基和杂芳基中的一个或多个取代基所取代；
R 6选自氢原子、烷基、卤代烷基、羟基、氨基、环烷基、杂环基、芳基、杂 芳基和羧基保护基；
R 7和R 8相同或不同，且各自独立地选自氢原子、烷基、卤代烷基、环烷基、杂环基、-C(O)OR 6和-OC(O)OR 9，其中所述的环烷基和杂环基任选进一步被选自氘原子、卤素、烷基、烷氧基、卤代烷基、氧代基、氨基、硝基、氰基、羟基和羟烷基中的一个或多个取代基所取代；
R 9选自氢原子、烷基、烷氧基、卤代烷基、卤代烷氧基、氨基、环烷基、杂环基、芳基和杂芳基；
R 10为芳基或杂芳基，其中所述的芳基和杂芳基任选进一步被选自氢原子、氘原子、卤素、烷基、烷氧基、卤代烷基、氨基、硝基、氰基、羟基、羟烷基、环烷基、环烷基氧基和杂环基中的一个或多个取代基所取代；
LG为离去基团，优选卤素、取代的磺酰基氧基、R iR jN-、羟基、氰基、R kS-、取代或未取代的磷酰基氧基、取代的甲酰基氧基，其中R i、R j独立地选自氢原子、C 1～C 6烷基或氨基保护基，R k选自氢原子、C 1～C 6烷基；
n为0、1、2、3或4；
m为0、1或2；且
s为0、1、2、3或4。
在某些实施方式中，所述式III所示化合物与式II所示化合物在碱性物质存在的条件下反应。
所述碱性物质可以是Na 2CO 3、K 2CO 3、Cs 2CO 3、NaHCO 3，KHCO 3、Na 2HPO 4、K 2HPO 4、K 3PO 4、Na 3PO 4、LiHMDS、NaHMDS、KHMDS、Ba(OH) 2、LiOR a、NaOR a、KOR a、CsOR a、TlOR a、NR bR cR d、DBU、DBN、Mg(OR a) 2，LiR e、NaNH 2、KNH 2、LiNH 2、LiH、NaH、KH、CaH 2、MgH 2、R fMgX、KF、CsF、Bu 4F、季铵盐中的一种或多种，其中R a独立地选自氢原子或C 1～C 6烷基，R b、R c、R d各独立地选自氢原子、烷基、环烷基，R e选自iBu，nBu，tBu，环己基，苯基，2,2,6,6-四甲基哌啶基，R f为C 1～C 6烷基，X为卤素，所述碱性物质优选tBuOK、LiHMDS、NaHMDS、KHMDS、LiH、NaH、KH、CaH 2、MgH 2、TBAI、TBAF、TBAB、TBAC、Na 2CO 3、K 2CO 3、Cs 2CO 3、K 3PO 4、Na 3PO 4中的一种或多种。
所述反应使用的溶剂可以是常规溶剂，例如水、二甲基甲酰胺、1-甲基-2-吡咯烷酮、四氢呋喃、甲基四氢呋喃、二氧六环、甲苯、二甲苯、二甲亚砜、乙醚、异丙醚、甲基叔丁基醚、乙腈、丙腈、C 1～C 6烷基醇、丙酮、乙酸乙酯中的一种或多种。
所述反应的反应温度可以是-20℃～100℃，优选-20℃～60℃，更优选-10℃～40℃。
在某些实施方式中，式II所示化合物与碱性物质的摩尔比可以是1:1～1:20，优选1:1～1:8。
在某些实施方式中，所述取代的磺酰基氧基可以是C 1～C 6烷基磺酰基氧基、全氟C 1～C 6烷基磺酰基氧基、芳基磺酰基氧基、芳烷基磺酰基氧基、杂芳基磺酰基 氧基。
C 1～C 6烷基磺酰基氧基的具体例子包括C 1～C 6直链或支链的烷基磺酰基氧基，例如甲基磺酰基氧基、乙基磺酰基氧基、正丙基磺酰基氧基、异丙基磺酰基氧基、正丁基磺酰基氧基、叔丁基磺酰基氧基、正戊基磺酰基氧基和正己基磺酰基氧基。
全氟C 1～C 6烷基磺酰基氧基的具体例子包括C 1～C 6直链或支链的全氟烷基磺酰基氧基，例如三氟甲基磺酰基氧基、1,1,2,2,2-五氟-1-乙基磺酰基氧基、1,1,2,2,3,3,3-七氟-1-丙基磺酰基氧基和1,1,2,2,3,3,4,4,4-九氟-1-丁基磺酰基氧基。
芳基磺酰基氧基的例子包括：任选地在苯环上具有1至3个选自由C 1～C 6直链或支链的烷基、C 1～C 6直链或支链的烷、硝基和卤原子组成的组的取代基的苯基磺酰基氧基和萘基磺酰基氧基。任选地具有取代基的苯基磺酰基氧基的具体例子包括苯基磺酰基氧基、4-甲基苯基磺酰基氧基、2-甲基苯基磺酰基氧基、4-硝基苯基磺酰基氧基、4-甲苯基磺酰基氧基、2-硝基苯基磺酰基氧基、3-氯苯基磺酰基氧基等等。萘基磺酰基氧基的具体例子包括α-萘基磺酰基氧基、β-萘基磺酰基氧基等等。
芳烷基磺酰基氧基的例子包括：被苯基(其任选地在苯环上具有1至3个选自C 1～C 6直链或支链的烷基、C 1～C 6直链或支链的烷、硝基和卤原子的取代基)取代的C 1～C 6直链或支链的烷基磺酰基氧基；和被萘基取代的C 1～C 6直链或支链的烷基磺酰基氧基。被苯基取代的烷基磺酰基氧基的具体例子包括苄基磺酰基氧基、2-苯基乙基磺酰基氧基、4-苯基丁基磺酰基氧基、4-甲基苄基磺酰基氧基、2-甲基苄基磺酰基氧基、4-硝基苄基磺酰基氧基、4-甲苄基磺酰基氧基、3-氯苄基磺酰基氧基等等。被萘基取代的烷基磺酰基氧基的具体例子包括α-萘基甲基磺酰基氧基、β-萘基甲基磺酰基氧基等等。
取代的磷酰基氧基、取代的甲酰基氧基的例子与取代的磺酰基氧基的取代基例子基本一致。
在某些实施方式中，所述离去基团可以是对甲苯磺酰基氧基、三氟甲磺酰基氧基、甲磺酰基氧基、对硝基苯磺酰基氧基等。
在某些实施方式中，所述通式II所示的化合物为式IIa所示的化合物，
Figure PCTCN2019096504-appb-000003
其中，L 1、R 3、R 4、LG的定义如前所述。
在某些实施方式中，所述通式II所示的化合物为式IIb所示的化合物，
Figure PCTCN2019096504-appb-000004
其中，LG为离去基团，优选卤素、取代的磺酰基氧基、R iR jN-、羟基、氰基、R kS-、取代或未取代的磷酰基氧基、取代的甲酰基氧基，其中R i、R j独立地选自氢原子、C 1～C 6烷基或氨基保护基，R k选自氢原子、C 1～C 6烷基；
更优选卤素、C 1～C 6烷基磺酰基氧基、全氟C 1～C 6烷基磺酰基氧基、芳基磺酰基氧基、芳烷基磺酰基氧基、杂芳基磺酰基氧基、R iR jN-、羟基、氰基、R kS-、取代或未取代的磷酰基氧基、取代的甲酰基氧基；
Y选自氢原子和羧基保护基，优选氢原子、甲基、乙基、烯丙基、异戊烯基和三甲基硅基乙基。
在某些实施方式中，所述通式II所示的化合物为式IIc所示的化合物，
Figure PCTCN2019096504-appb-000005
其中，LG为离去基团，优选卤素、取代的磺酰基氧基、R iR jN-、羟基、R kS-、取代或未取代的磷酰基氧基、取代的甲酰基氧基，其中R i、R j独立地选自氢原子、C 1～C 6烷基或氨基保护基，R k选自氢原子、C 1～C 6烷基；
更优选卤素、C 1～C 6烷基磺酰基氧基、全氟C 1～C 6烷基磺酰基氧基、芳基磺酰基氧基、芳烷基磺酰基氧基、杂芳基磺酰基氧基、R iR jN-、羟基、R kS-、取代或未取代的磷酰基氧基、取代的甲酰基氧基；
Y选自氢原子和羧基保护基，优选氢原子、甲基、乙基、烯丙基、异戊烯基和三甲基硅基乙基。
在某些实施方式中，所述通式III所示的化合物为式IIIa所示的化合物，
Figure PCTCN2019096504-appb-000006
其中，R 1相同或不同，且各自独立地选自氢原子、卤素、烷基、卤代烷基、 烷氧基、卤代烷氧基、氨基、硝基、氰基、羟基、羟烷基、环烷基、杂环基、芳基和杂芳基；
R 5选自烷基、环烷基和卤代烷基，其中所述的烷基或环烷基任选进一步被选自氘原子、卤素、烷基和环烷基中的一个或多个取代基所取代；
R 2、n的定义如前所述。
在某些实施方式中，所述通式III所示的化合物为式IIIb所示的化合物，
Figure PCTCN2019096504-appb-000007
在某些实施方式中，所述通式III所示的化合物为式IIIc所示的化合物，
Figure PCTCN2019096504-appb-000008
在某些实施方式中，所述制备方法还包括式IV所示化合物与式V所示化合物反应制备式II所示化合物的步骤，
Figure PCTCN2019096504-appb-000009
其中，R 11选自-OR 9、卤素；
LG’与LG相同或不同，选自卤素、取代的磺酰基氧基、R iR jN-、羟基、R kS-、取代或未取代的磷酰基氧基、取代的甲酰基氧基，其中R i、R j独立地选自氢原子、C 1～C 6烷基或氨基保护基，R k选自氢原子、C 1～C 6烷基；
L 1、R 3、R 4、R 9、LG、s的定义如前所述。
本公开另一方面提供了式IIb所示的化合物，
Figure PCTCN2019096504-appb-000010
其中，LG为离去基团，优选卤素、取代的磺酰基氧基、R iR jN-、羟基、氰基、R kS-、取代的甲酰基氧基，其中R i、R j独立地选自氢原子、C 1～C 6烷基或氨基保护基，R k选自氢原子、C 1～C 6烷基；
更优选卤素、C 1～C 6烷基磺酰基氧基、全氟C 1～C 6烷基磺酰基氧基、芳基磺酰基氧基、芳烷基磺酰基氧基、杂芳基磺酰基氧基、R iR jN-、羟基、氰基、R kS-、取代的甲酰基氧基；
Y选自氢原子和羧基保护基，优选氢原子、甲基、乙基、烯丙基、异戊烯基和三甲基硅基乙基；
并且当LG为羟基时，Y不为甲基。
本公开另一方面提供了式IIb所示的化合物的制备方法，包括式IVb所示化合物或其盐与式Vb所示化合物或其盐反应的步骤，
Figure PCTCN2019096504-appb-000011
其中，R 11选自-OR 9、卤素；R 9选自氢原子、烷基、烷氧基、卤代烷基、卤代烷氧基、氨基、环烷基、杂环基、芳基和杂芳基；LG’与LG相同或不同，选自卤素、取代的磺酰基氧基、R iR jN-、羟基、R kS-、取代或未取代的磷酰基氧基、取代的甲酰基氧基，其中R i、R j独立地选自氢原子、C 1～C 6烷基或氨基保护基，R k选自氢原子、C 1～C 6烷基；LG、Y的定义如式IIb所示的化合物中定义所述。
在某些实施方式中，式IVb所示化合物的盐可以是钠盐、钾盐、胺盐等。
在某些实施方式中，式Vb所示化合物的盐可以是盐酸盐、硫酸盐、磷酸盐、乙酸盐等。
本公开另一方面提供了式IIc所示的化合物，
Figure PCTCN2019096504-appb-000012
其中，LG为离去基团，优选卤素、取代的磺酰基氧基、R iR jN-、羟基、R kS-、取代或未取代的磷酰基氧基、取代的甲酰基氧基，其中R i、R j独立地选自氢原子、C 1～C 6烷基或氨基保护基，R k选自氢原子、C 1～C 6烷基；
更优选卤素、C 1～C 6烷基磺酰基氧基、全氟C 1～C 6烷基磺酰基氧基、芳基磺酰 基氧基、芳烷基磺酰基氧基、杂芳基磺酰基氧基、R iR jN-、羟基、R kS-、取代的甲酰基氧基；
Y选自氢原子和羧基保护基，优选氢原子、甲基、乙基、烯丙基、异戊烯基和三甲基硅基乙基。
本公开另一方面提供了式IIc所示的化合物的制备方法，包括式IVc所示化合物或其盐与式Vb所示化合物或其盐反应的步骤，
Figure PCTCN2019096504-appb-000013
其中，R 11选自-OR 9、卤素；R 9选自氢原子、烷基、烷氧基、卤代烷基、卤代烷氧基、氨基、环烷基、杂环基、芳基和杂芳基；LG’与LG相同或不同，选自卤素、取代的磺酰基氧基、R iR jN-、羟基、R kS-、取代或未取代的磷酰基氧基、取代的甲酰基氧基，其中R i、R j独立地选自氢原子、C 1～C 6烷基或氨基保护基，R k选自氢原子、C 1～C 6烷基；LG、Y的定义如式IIc所示的化合物中定义所述。
在某些实施方式中，式IVc所示化合物的盐可以是钠盐、钾盐、胺盐等。
在某些实施方式中，式Vb所示化合物的盐可以是盐酸盐、硫酸盐、磷酸盐、乙酸盐等。
本公开另一方面还提供了式IVd所示的化合物，
Figure PCTCN2019096504-appb-000014
其中，Y1选自氢原子或羧基保护基；Y2选自氢原子或羟基保护基。
本公开另一方面还提供了一种式IVd所示的化合物的制备方法，包括式IVe所示的化合物转化为式IVd所示的化合物的步骤，
Figure PCTCN2019096504-appb-000015
本公开另一方面还提供了一种式I所示的化合物或其药学上可接受的盐的制备 方法，包括式IIIb所示化合物与式IIb所示化合物反应制备式BI所示化合物的步骤，其中，LG、Y的定义如前所述，
Figure PCTCN2019096504-appb-000016
在某些实施方式中，所述式IIIb所示化合物与式IIb所示化合物在碱性物质存在的条件下反应。
所述碱性物质可以是Na 2CO 3、K 2CO 3、Cs 2CO 3、NaHCO 3，KHCO 3、Na 2HPO 4、K 2HPO 4、K 3PO 4、Na 3PO 4、LiHMDS、NaHMDS、KHMDS、Ba(OH) 2、LiOR a、NaOR a、KOR a、CsOR a、TlOR a、NR bR cR d、DBU、DBN、Mg(OR a) 2，LiR e、NaNH 2、KNH 2、LiNH 2、LiH、NaH、KH、CaH 2、MgH 2、R fMgX、KF、CsF、Bu 4F、季铵盐中的一种或多种，其中R a独立地选自氢原子或C 1～C 6烷基，R b、R c、R d各独立地选自氢原子、烷基、环烷基，R e选自iBu，nBu，tBu，环己基，苯基，2,2,6,6-四甲基哌啶基，R f为C 1～C 6烷基，X为卤素，所述碱性物质优选tBuOK、LiHMDS、NaHMDS、KHMDS、LiH、NaH、KH、CaH 2、MgH 2、TBAI、TBAF、TBAB、TBAC、Na 2CO 3、K 2CO 3、Cs 2CO 3、K 3PO 4、Na 3PO 4。
所述反应使用的溶剂可以是常规溶剂，例如水、二甲基甲酰胺、1-甲基-2-吡咯烷酮、四氢呋喃、甲基四氢呋喃、二氧六环、甲苯、二甲苯、二甲亚砜、乙醚、异丙醚、甲基叔丁基醚、乙腈、丙腈、C 1～C 6烷基醇、丙酮、乙酸乙酯中的一种或 多种。
所述反应的反应温度可以是-20℃～100℃，优选-20℃～60℃，更优选-10℃～40℃。
在某些实施方式中，式IIb所示化合物与碱性物质的摩尔比可以是1:1～1:20，优选1:1～1:8。
在某些实施方式中，所述方法还可包括本公开所述的制备式IIb所示的化合物的步骤。
在某些实施方式中，LG选自取代的磺酰基氧基，所述方法还包括式IIcIId所示的化合物转化为式IIb所示的化合物的步骤，
Figure PCTCN2019096504-appb-000017
所述式IIcIId所示的化合物可通过本公开所述的式II所示化合物的制备方法制备。
在某些实施方式中，当Y选自羧基保护基时，所述方法还可包括式BI所示化合物脱羧基保护基的步骤。
本公开另一方面还提供了一种式VI所示化合物或其药学上可接受的盐的制备方法，包括式IIIc所示化合物与式IIc所示化合物反应制备式BVI所示化合物的步骤，其中，LG、Y的定义如前所述，
Figure PCTCN2019096504-appb-000018
Figure PCTCN2019096504-appb-000019
在某些实施方式中，所述式IIIc所示化合物与式IIc所示化合物在碱性物质存在的条件下反应。
所述碱性物质可以是Na 2CO 3、K 2CO 3、Cs 2CO 3、NaHCO 3，KHCO 3、Na 2HPO 4、K 2HPO 4、K 3PO 4、Na 3PO 4、LiHMDS、NaHMDS、KHMDS、Ba(OH) 2、LiOR a、NaOR a、KOR a、CsOR a、TlOR a、NR bR cR d、DBU、DBN、Mg(OR a) 2，LiR e、NaNH 2、KNH 2、LiNH 2、LiH、NaH、KH、CaH 2、MgH 2、R fMgX、KF、CsF、Bu 4F、季铵盐中的一种或多种，其中R a独立地选自氢原子或C 1～C 6烷基，R b、R c、R d各独立地选自氢原子、烷基、环烷基，R e选自iBu，nBu，tBu，环己基，苯基，2,2,6,6-四甲基哌啶基，R f为C 1～C 6烷基，X为卤素，所述碱性物质优选tBuOK、LiHMDS、NaHMDS、KHMDS、LiH、NaH、KH、CaH 2、MgH 2、TBAI、TBAF、TBAB、TBAC、Na 2CO 3、K 2CO 3、Cs 2CO 3、K 3PO 4、Na 3PO 4。
所述反应使用的溶剂可以是常规溶剂，例如水、二甲基甲酰胺、1-甲基-2-吡咯烷酮、四氢呋喃、甲基四氢呋喃、二氧六环、甲苯、二甲苯、二甲亚砜、乙醚、异丙醚、甲基叔丁基醚、乙腈、丙腈、C 1～C 6烷基醇、丙酮、乙酸乙酯中的一种或多种。
所述反应的反应温度可以是-20℃～100℃，优选-20℃～60℃，更优选-10℃～40℃。
在某些实施方式中，式IIc所示化合物与碱性物质的摩尔比可以是1:1～1:20，优选1:1～1:8。
在某些实施方式中，所述方法还可包括本公开所述的制备式IIc所示的化合物的步骤。
在某些实施方式中，LG选自取代的磺酰基氧基，所述方法还包括式IIe所示的化合物转化为式IIc所示的化合物的步骤，
Figure PCTCN2019096504-appb-000020
所述式IIe所示的化合物可通过本公开所述的式II所示化合物的制备方法制备。
在某些实施方式中，当Y选自羧基保护基时，所述方法还可包括式BVI所示化合物脱羧基保护基的步骤。
本公开所述的FXIa抑制剂及其中间体的制备方法，通过手性合成方法，直接合成立体异构的目标产物，无需拆分消旋体。整个反应过程产物的光学纯度都得到了保持，反应收率也大大提高，利于工业化生产。
除非有相反陈述，在说明书和权利要求书中使用的术语具有下述含义。
术语“烷基”指饱和脂肪族烃基团，其为包含1至20个碳原子的直链或支链基团，优选含有1至12个碳原子的烷基。非限制性实例包括甲基、乙基、正丙基、异丙基、正丁基、异丁基、叔丁基、仲丁基、正戊基、1,1-二甲基丙基、1,2-二甲基丙基、2,2-二甲基丙基、1-乙基丙基、2-甲基丁基、3-甲基丁基、正己基、1-乙基-2-甲基丙基、1,1,2-三甲基丙基、1,1-二甲基丁基、1,2-二甲基丁基、2,2-二甲基丁基、1,3-二甲基丁基、2-乙基丁基、2-甲基戊基、3-甲基戊基、4-甲基戊基、2,3-二甲基丁基、正庚基、2-甲基己基、3-甲基己基、4-甲基己基、5-甲基己基、2,3-二甲基戊基、2,4-二甲基戊基、2,2-二甲基戊基、3,3-二甲基戊基、2-乙基戊基、3-乙基戊基、正辛基、2,3-二甲基己基、2,4-二甲基己基、2,5-二甲基己基、2,2-二甲基己基、3,3-二甲基己基、4,4-二甲基己基、2-乙基己基、3-乙基己基、4-乙基己基、2-甲基-2-乙基戊基、2-甲基-3-乙基戊基、正壬基、2-甲基-2-乙基己基、2-甲基-3-乙基己基、2,2-二乙基戊基、正癸基、3,3-二乙基己基、2,2-二乙基己基，及其各种支链异构体等。更优选的是含有1至6个碳原子的低级烷基，非限制性实施例包括甲基、乙基、正丙基、异丙基、正丁基、异丁基、叔丁基、仲丁基、正戊基、1,1-二甲基丙基、1,2-二甲基丙基、2,2-二甲基丙基、1-乙基丙基、2-甲基丁基、3-甲基丁基、正己基、1-乙基-2-甲基丙基、1,1,2-三甲基丙基、1,1-二甲基丁基、1,2-二甲基丁基、2,2-二甲基丁基、1,3-二甲基丁基、2-乙基丁基、2-甲基戊基、3-甲基戊基、4-甲基戊基、2,3-二甲基丁基等。烷基可以是取代的或非取代的，当被取代时，取代基可以在任何可使用的连接点上被取代，所述取代基优选为一个或多个以下基团，其独立地选自烷基、烯基、炔基、烷氧基、烷硫基、烷基氨基、卤素、巯基、羟基、硝基、氰基、环烷基、杂环烷基、芳基、杂芳基、环烷氧基、杂环烷氧基、环烷硫基、杂环烷硫基、氧代基、羧基或羧酸酯基。
术语“亚烷基”指饱和的直链或支链脂肪族烃基，其具有2个从母体烷的相同碳原子或两个不同的碳原子上除去两个氢原子所衍生的残基，其为包含1至20个碳原子的直链或支链基团，优选含有1至12个碳原子，更优选含有1至6个碳原子的亚烷基。亚烷基的非限制性实例包括但不限于亚甲基(-CH 2-)、1,1-亚乙基(-CH(CH 3)-)、1,2-亚乙基(-CH 2CH 2)-、1,1-亚丙基(-CH(CH 2CH 3)-)、1,2-亚丙基(-CH 2CH(CH 3)-)、1,3-亚丙基(-CH 2CH 2CH 2-)、1,4-亚丁基(-CH 2CH 2CH 2CH 2-)等。亚 烷基可以是取代的或非取代的，当被取代时，取代基可以在任何可使用的连接点上被取代。
术语“环烷基”指饱和或部分不饱和单环或多环环状烃取代基，环烷基环包含3至20个碳原子，优选包含3至12个碳原子，更优选包含3至6个碳原子。单环环烷基的非限制性实例包括环丙基、环丁基、环戊基、环戊烯基、环己基、环己烯基、环己二烯基、环庚基、环庚三烯基、环辛基等；多环环烷基包括螺环、稠环和桥环的环烷基。
术语“杂环基”指饱和或部分不饱和单环或多环环状烃取代基，其包含3至20个环原子，其中一个或多个环原子为选自氮、氧或S(O) m(其中m是整数0至2)的杂原子，但不包括-O-O-、-O-S-或-S-S-的环部分，其余环原子为碳。优选包含3至12个环原子，其中1～4个是杂原子；更优选包含3至6个环原子。单环杂环基的非限制性实例包括吡咯烷基、咪唑烷基、四氢呋喃基、四氢噻吩基、二氢咪唑基、二氢呋喃基、二氢吡唑基、二氢吡咯基、哌啶基、哌嗪基、吗啉基、硫代吗啉基、高哌嗪基等，优选哌啶基、吡咯烷基。多环杂环基包括螺环、稠环和桥环的杂环基。
术语“芳基”指具有共轭的π电子体系的6至14元全碳单环或稠合多环(也就是共享毗邻碳原子对的环)基团，优选为6至10元，例如苯基和萘基。所述芳基环可以稠合于杂芳基、杂环基或环烷基环上，其中与母体结构连接在一起的环为芳基环，其非限制性实例包括：
Figure PCTCN2019096504-appb-000021
芳基可以是取代的或非取代的，当被取代时，取代基优选为一个或多个以下基团，其独立地选自烷基、烯基、炔基、烷氧基、烷硫基、烷基氨基、卤素、巯基、羟基、硝基、氰基、环烷基、杂环烷基、芳基、杂芳基、环烷氧基、杂环烷氧基、环烷硫基、杂环烷硫基、羧基或羧酸酯基，优选苯基。
术语“杂芳基”指包含1至4个杂原子、5至14个环原子的杂芳族体系，其中杂原子选自氧、硫和氮。杂芳基优选为5至12元，例如咪唑基、呋喃基、噻吩基、噻唑基、吡唑基、噁唑基、吡咯基、四唑基、吡啶基、嘧啶基、噻二唑、吡嗪基等，优选为咪唑基、吡唑基、嘧啶基或噻唑基；更优选为吡唑基或噻唑基。所述杂芳基环可以稠合于芳基、杂环基或环烷基环上，其中与母体结构连接在一起的 环为杂芳基环，其非限制性实例包括：
Figure PCTCN2019096504-appb-000022
杂芳基可以是任选取代的或非取代的，当被取代时，取代基优选为一个或多个以下基团，其独立地选自烷基、烯基、炔基、烷氧基、烷硫基、烷基氨基、卤素、巯基、羟基、硝基、氰基、环烷基、杂环烷基、芳基、杂芳基、环烷氧基、杂环烷氧基、环烷硫基、杂环烷硫基、羧基或羧酸酯基。
术语“烷氧基”指-O-(烷基)和-O-(非取代的环烷基)，其中烷基的定义如上所述。烷氧基的非限制性实例包括：甲氧基、乙氧基、丙氧基、丁氧基、环丙氧基、环丁氧基、环戊氧基、环己氧基。烷氧基可以是任选取代的或非取代的，当被取代时，取代基优选为一个或多个以下基团，其独立地选自烷基、烯基、炔基、烷氧基、烷硫基、烷基氨基、卤素、巯基、羟基、硝基、氰基、环烷基、杂环烷基、芳基、杂芳基、环烷氧基、杂环烷氧基、环烷硫基、杂环烷硫基、羧基或羧酸酯基。
术语“烷硫基”指-S-(烷基)和-S-(非取代的环烷基)，其中烷基的定义如上所述。烷硫基的非限制性实例包括：甲硫基、乙硫基、丙硫基、丁硫基、环丙硫基、环丁硫基、环戊硫基、环己硫基。烷硫基可以是任选取代的或非取代的，当被取代时，取代基优选为一个或多个以下基团，其独立地选自烷基、烯基、炔基、烷氧基、烷硫基、烷基氨基、卤素、巯基、羟基、硝基、氰基、环烷基、杂环烷基、芳基、杂芳基、环烷氧基、杂环烷氧基、环烷硫基、杂环烷硫基中的一个或多个取代基所取代。
术语“卤素”指氟、氯、溴或碘。
“羧基保护基”是本领域已知的适当的用于羧基保护的基团，参见文献(“Protective Groups in Organic Synthesis”，5 Th Ed.T.W.Greene&P.G.M.Wuts)中的羧基保护基团，作为示例，优选地，所述的羧基保护基可以是取代或非取代的C 1-10的直链或支链烷基、取代或非取代的C 2-10的直链或支链烯基或炔基、取代或非取代的C 3-8的环状烷基、取代或非取代的C 5-10的芳基或杂芳基、或(C 1-8烷基或芳基) 3硅烷基；优选C 1-6的直链或支链烷基，更优选C 1-4的直链或支链烷基。例如，甲基、乙基、烯丙基、异戊烯基、三甲基硅基乙基等。
“氨基保护基”是本领域已知的适当的用于氨基保护的基团，参见文献(“Protective Groups in Organic Synthesis”，5 Th.Ed.T.W.Greene&P.G.M.Wuts) 中的氨基保护基团，优选地，所述的氨基保护基可以是(C 1-10烷基或芳香基)酰基，例如：甲酰基，乙酰基，苯甲酰基等；可以是(C 1-6烷基或C 6-10芳基)磺酰基；也可以是(C 1-6烷氧基或C 6-10芳基氧基)羰基、Boc或Cbz；还可以是烷基，例如：三苯甲基(Tr)、2,4-二甲氧基苄基(DMB)、对甲氧基苄基(PMB)或苄基(Bn)。
“羟基保护基”是本领域已知的适当的用于羟基保护的基团，参见文献(“Protective Groups in Organic Synthesis”，5 Th Ed.T.W.Greene&P.G.M.Wuts)中的羟基保护基团。作为示例，优选地，所述的羟基保护基可以是(C 1-10烷基或芳基) 3硅烷基，例如：三乙基硅基，三异丙基硅基，叔丁基二甲基硅基，叔丁基二苯基硅基等；可以是C 1-10烷基或取代烷基，优选烷氧基或芳基取代的烷基，更优选C 1-6烷氧基取代的C 1-6烷基或苯基取代的C 1-6烷基，最优选C 1-4烷氧基取代的C 1-4烷基，例如：甲基，叔丁基，烯丙基，苄基，甲氧基甲基(MOM)，乙氧基乙基，2-四氢吡喃基(THP)等；可以是(C 1-10烷基或芳香基)酰基，例如：甲酰基，乙酰基，苯甲酰基等；可以是(C 1-6烷基或C 6-10芳基)磺酰基；也可以是(C 1-6烷氧基或C 6-10芳基氧基)羰基。
“任选”或“任选地”意味着随后所描述地事件或环境可以但不必发生，该说明包括该事件或环境发生或不发生地场合。例如，“任选被烷基取代的杂环基团”意味着烷基可以但不必须存在，该说明包括杂环基团被烷基取代的情形和杂环基团不被烷基取代的情形。
本公开所述化合物的化学结构中，键
Figure PCTCN2019096504-appb-000023
并未指定构型，即如果化学结构中存在构型异构，键
Figure PCTCN2019096504-appb-000024
可以为
Figure PCTCN2019096504-appb-000025
或
Figure PCTCN2019096504-appb-000026
或者同时包含
Figure PCTCN2019096504-appb-000027
和
Figure PCTCN2019096504-appb-000028
两种构型。
具体实施方式
以下将结合具体实例详细地解释本公开，使得本专业技术人员更全面地理解本公开具体实例仅用于说明本公开的技术方案，并不以任何方式限定本公开。
实施例1
Figure PCTCN2019096504-appb-000029
第一步
将化合物1(40.1g，292.41mmol)溶于500mL DMF中，加入碳酸钾(40.41g，292.41mmol)，冰浴冷却，再加入丙烯基溴(35.37g，292.41mmol)，室温反应。反应结束后，向反应液中加入1500mL的水，用乙酸乙酯萃取，合并有机相，依次用饱和氯化钠和水洗，无水硫酸钠干燥，过滤，滤液减压浓缩，所得残余物用硅胶柱层析纯化(洗脱剂：正己烷:乙酸乙酯＝10:1)，收集产品浓缩后得化合物2共33.7g，产率65％。
MS m/z(LC-MS):178.2[M+1]
第二步
将化合物2(532mg，3mmol)，D-苯基乳酸(化合物3，500mg，3mmol)和甲基硼酸(18mg，0.3mmol)置于反应瓶中，加入20mL甲苯和108uL水，升温至140℃，回流分水反应。反应结束后，反应液冷却至室温，加入100mL二氯甲烷，依次用0.5M盐酸和1M碳酸氢钠溶液洗涤，无水硫酸钠干燥，过滤，滤液减压浓缩，用Combiflash(洗脱剂：二氯甲烷100％)纯化所得残余物，得到化合物4共829mg，产率84.9％。
MS m/z(LC-MS):326.2[M+1]
第三步
将化合物4(4.3g，13.22mmol)溶于50mL四氢呋喃，氩气置换后冰浴冷却，加入三乙胺(2.67g，26.43mmol)，再滴加入甲烷磺酰氯(2.27mg，19.82mmol)，冰浴反应。反应结束后，反应液中加入1M稀盐酸淬灭反应，分液，水相用乙酸乙酯萃取，合并有机相，饱和氯化钠水溶液洗，无水硫酸钠干燥，过滤，滤液浓缩，粗品用甲基叔丁基醚打浆，过滤干燥得到化合物5共4.6g，产率86.27％。
MS m/z(LC-MS):404.1[M+1]
实施例2
Figure PCTCN2019096504-appb-000030
第一步
将化合物IIIb(6.54g，23.55mmol，根据WO2018041122公开的方法制备)溶于200mL四氢呋喃中，加入四丁基碘化铵(7.84g，23.55mmol)和叔丁醇钾(3.96g，35.32mmol)，氩气氛围下冷却至0℃后，加入化合物5(9.5g，23.55mmol)，保温反应。反应结束后，反应液中加入1M的盐酸淬灭反应，加入50ml乙酸乙酯和100mL水搅拌，分液，水相用乙酸乙酯萃取，合并有机相，用饱和氯化钠溶液洗涤，无水硫酸钠干燥，过滤，滤液减压浓缩，用硅胶柱层色谱法以洗脱剂正己烷:乙酸乙酯:二氯甲烷＝10:3:1纯化所的残余物，得到化合物6共8.1g，产率58.8％，光学纯度：95.7％。
第二步
将化合物6(8.10g，13.85mmol)溶于81mL四氢呋喃中，氩气氛围下，冷却至0℃，加入吡咯烷(984.67mg，13.85mmol)和四(三苯基膦)钯(1.60g，1.38mmol)，0℃搅拌反应。反应结束后，反应液中加入1M盐酸淬灭反应，加入40mL水，搅拌，过滤，滤液分液，水相用乙酸乙酯萃取，合并有机相，用饱和氯化钠溶液洗涤，无水硫酸钠干燥，过滤，滤液减压浓缩，所得残余物中加入80mL甲醇，升温至50℃打浆30分钟后自然冷却至室温搅拌30分钟，过滤，收集滤饼，干燥，得到式I所示化合物6.48g，产率85.88％，光学纯度：93.8％。
实施例3
Figure PCTCN2019096504-appb-000031
第一步
称取(R)-苹果酸40g于反应瓶中，加入250g三氟乙酸酐，室温反应2h，蒸除溶剂后加入BnOH(167mL)室温条件下搅拌反应。反应结束后，向体系加入碳酸氢钠溶液，用乙酸乙酯萃取，水相用盐酸调至酸性，乙酸乙酯萃取，收集合并有机相，浓缩得到化合物8共69g。
第二步
称取化合物8(69g)于反应瓶中，加入65.1g乙酸酐、490mg无水氯化铁，室温反应。反应结束后，反应液加入乙腈溶解，加入到饱和碳酸氢钠溶液中搅拌，乙酸乙酯萃取，水相用盐酸调至酸性，乙酸乙酯萃取，收集合并有机相，浓缩得到化合物9共56.5g，产率70％。
第三步
称取化合物9(56.5g)于反应瓶中，加入200mL四氢呋喃，降至0℃，滴加10.0M硼烷二甲硫醚溶液(42mL)。滴毕，室温搅拌反应，反应结束后，加入甲醇淬灭反应。体系浓缩，得到化合物10共49.4g，产率92％。
第四步
称取化合物10(29g)和三氯乙酰亚胺叔丁酯(37.6g)、二氯甲烷230mL于反应瓶中，搅拌溶解，降至-40℃，加入TBSOTf(3.9mL)。反应结束后，加入三乙胺淬灭，体系浓缩，残余物用乙酸乙酯打浆，过滤，浓缩得到化合物11共23.4g，产率66％。
MS m/z(LC-MS):331.05[M+23]
第五步
称取化合物11(26.5g)和10％Pd/C 7.9g、四氢呋喃86mL于反应瓶中，搅拌，在1atm下氢化反应。反应结束后，过滤，经DCM:CH 3OH＝5:1作洗脱剂柱层析纯化，得到化合物12共15.8g，产率85％。
MS m/z(LC-MS):219.05[M+1]
第六步
称取化合物12(6.04g)和二氯甲烷60mL、DMF 0.1mL于反应瓶中，加入3.5mL草酰氯，加热至30℃反应1h，浓缩至干，溶于30mL二氯甲烷备用。
称取5.03g化合物2、50mL二氯甲烷和11.43mL DIEA于反应瓶中搅拌，加入上述二氯甲烷溶液。反应结束后，加入100mL二氯甲烷，用饱和碳酸氢钠溶液洗涤，无水硫酸钠干燥，有机相浓缩得到化合物13共9.5g。
MS m/z(LC-MS):378.10[M+1]
第七步
称取化合物13(9.18g)和异丙醇90mL于反应瓶中，加入6.72g碳酸钾，加热至50℃搅拌反应。反应结束后，过滤，滤液浓缩至干，加入甲基叔丁基醚100mL溶解，过滤，滤液浓缩至干，得化合物14共7.76g。
MS m/z(LC-MS):336.10[M+1]
第八步
称取化合物14(7.76g)和二氯甲烷80mL于反应瓶中，加入6.43mL三乙胺和7.69g对硝基苯磺酰氯，室温搅拌反应。反应结束后，加入100mL二氯甲烷，依次用饱和碳酸氢钠溶液和饱和氯化铵洗涤，无水硫酸钠干燥，浓缩反应体系，残余物用正庚烷：二氯甲烷＝50：1(30mL)打浆，过滤，干燥得到化合物15共8.23g。
MS m/z(LC-MS):521.00[M+1]
实施例4
Figure PCTCN2019096504-appb-000032
第一步
称取化合物IIIc(50mg，根据WO2018041122公开的方法制备)溶于1mL二氧六环中，加入化合物15(9.5g，23.55mmol)和Cs 2CO 3粉末168mg，室温反应。反应结束后，过滤，滤液浓缩至干，用乙酸乙酯:石油醚＝1:1作洗脱剂柱层析纯化，得到化合物16共65mg，光学纯度96.5％。
第二步
称取化合物16(1g)溶于6mL四氢呋喃中，搅拌下加入0.148mL吡咯烷和24mg Pd(dppf)Cl 2，室温反应。反应结束后，加入适量甲基叔丁基醚，用饱和碳酸钠水溶液萃取，水相用甲基叔丁基醚洗涤，盐酸调至pH为酸性后用乙酸乙酯萃取，有机相用饱和食盐水洗涤，无水硫酸钠干燥，浓缩得到化合物VI共0.84g，产率90.6％，光学纯度98％。
由于已根据其特殊的实施方案描述了本公开，某些修饰和等价变化对于精通此领域的技术人员是显而易见的且包括在本公开的范围内。

Claims (26)

  1. 一种如式AI所示化合物的制备方法，包括式III所示化合物与式II所示化合物反应的步骤，
    Figure PCTCN2019096504-appb-100001
    其中：
    环A为芳基或杂芳基；
    R 1相同或不同，且各自独立地选自氢原子、卤素、烷基、卤代烷基、烷氧基、卤代烷氧基、氨基、硝基、氰基、羟基、羟烷基、-C(O)R 5、环烷基、杂环基、芳基和杂芳基；
    R 2选自卤素、烷基、卤代烷基、烷氧基、环烷基氧基、卤代烷氧基、氨基、硝基、氰基、羟基、羟烷基和烷硫基，其中所述的烷基、烷氧基、卤代烷基、卤代烷氧基、羟烷基和烷硫基任选进一步被选自氘原子、卤素、烷氧基、卤代烷氧基、氨基、硝基、氰基、羟基和羟烷基中的一个或多个取代基所取代；
    L 1为亚烷基，其中所述的亚烷基任选进一步被卤素或氘原子中的一个或多个取代基所取代；
    R 3相同或不同，且各自独立地选自氢原子、烷基、烷氧基、氧代基、卤素、卤代烷基、卤代烷氧基、氨基、硝基、氰基、羟基、羟烷基、环烷基、杂环基、芳基、杂芳基、-C(O)R 6、-C(O)OR 6、-NHC(O)R 6、-NHC(O)OR 6、-NR 7R 8、-C(O)NR 7R 8、-CH 2NHC(O)OR 6、-CH 2NR 7R 8、-C(O)OCH(R 7)R 8和-S(O) mR 6，其中所述的烷基任选进一步被选自氘原子、卤素、烷氧基、卤代烷氧基、氨基、硝基、氰基、羟基、羟烷基、-NR 7R 8和-NHC(O)OR 6中的一个或多个取代基所取代；
    R 4选自氢原子、氘原子、卤素、烷基、烷氧基、氨基、硝基、氰基、羟基、羟烷基、环烷基、环烷基氧基、杂环基、芳基和杂芳基，其中所述的环烷基、杂环基、芳基和杂芳基任选进一步被选自氘原子、卤素、烷基、烷氧基、卤代烷基、氨基、硝基、氰基、羟基、羟烷基、环烷基、环烷基氧基、杂环基、-NHC(O)R 9和R 10中的一个或多个取代基所取代；
    R 5选自氢原子、烷基、卤代烷基、烷氧基、卤代烷氧基、氨基、羟基、羟烷 基、环烷基、杂环基、芳基和杂芳基，其中所述的烷基、烷氧基、环烷基、杂环基、芳基和杂芳基任选进一步被选自氢原子、氘原子、卤素、烷基、烷氧基、卤代烷氧基、氨基、硝基、氰基、羟基、羟烷基、环烷基、环烷基氧基、杂环基、芳基和杂芳基中的一个或多个取代基所取代；
    R 6选自氢原子、烷基、卤代烷基、羟基、氨基、环烷基、杂环基、芳基、杂芳基和羧基保护基；
    R 7和R 8相同或不同，且各自独立地选自氢原子、烷基、卤代烷基、环烷基、杂环基、-C(O)OR 6和-OC(O)OR 9，其中所述的环烷基和杂环基任选进一步被选自氘原子、卤素、烷基、烷氧基、卤代烷基、氧代基、氨基、硝基、氰基、羟基和羟烷基中的一个或多个取代基所取代；
    R 9选自氢原子、烷基、烷氧基、卤代烷基、卤代烷氧基、氨基、环烷基、杂环基、芳基和杂芳基；
    R 10为芳基或杂芳基，其中所述的芳基和杂芳基任选进一步被选自氢原子、氘原子、卤素、烷基、烷氧基、卤代烷基、氨基、硝基、氰基、羟基、羟烷基、环烷基、环烷基氧基和杂环基中的一个或多个取代基所取代；
    LG为离去基团，优选卤素、取代的磺酰基氧基、R iR jN-、羟基、R kS-、取代或未取代的磷酰基氧基、取代的甲酰基氧基，其中R i、R j独立地选自氢原子、C 1～C 6烷基或氨基保护基，R k选自氢原子、C 1～C 6烷基；
    n为0、1、2、3或4；
    m为0、1或2；且
    s为0、1、2、3或4。
  2. 根据权利要求1所述的制备方法，其特征在于，所述式III所示化合物与式II所示化合物在碱性物质存在的条件下反应，所述碱性物质优选Na 2CO 3、K 2CO 3、Cs 2CO 3、NaHCO 3，KHCO 3、Na 2HPO 4、K 2HPO 4、K 3PO 4、Na 3PO 4、LiHMDS、NaHMDS、KHMDS、Ba(OH) 2、LiOR a、NaOR a、KOR a、CsOR a、TlOR a、NR bR cR d、DBU、DBN、Mg(OR a) 2，LiR e、NaNH 2、KNH 2、LiNH 2、LiH、NaH、KH、CaH 2、MgH 2、R fMgX、KF、CsF、Bu 4F、季铵盐中的一种或多种，其中R a独立地选自氢原子或C 1～C 6烷基，R b、R c、R d各独立地选自氢原子、烷基、环烷基，R e选自iBu，nBu，tBu，环己基，苯基，2,2,6,6-四甲基哌啶基，R f为C 1～C 6烷基，X为卤素，所述碱性物质更优选tBuOK、LiHMDS、NaHMDS、KHMDS、LiH、NaH、KH、CaH 2、MgH 2、TBAI、TBAF、TBAB、TBAC、Na 2CO 3、K 2CO 3、Cs 2CO 3、K 3PO 4、Na 3PO 4中的一种或多种。
  3. 根据权利要求1所述的制备方法，其特征在于，所述取代的磺酰基氧基选自C 1～C 6烷基磺酰基氧基、全氟C 1～C 6烷基磺酰基氧基、芳基磺酰基氧基、芳烷基磺 酰基氧基、杂芳基磺酰基氧基。
  4. 根据权利要求1所述的制备方法，其特征在于，式II所示化合物为
    Figure PCTCN2019096504-appb-100002
    其中：L 1、R 3、R 4、LG的定义如权利要求1所述。
  5. 根据权利要求1所述的制备方法，其特征在于，式II所示化合物为
    Figure PCTCN2019096504-appb-100003
    其中，LG为离去基团，优选卤素、取代的磺酰基氧基、R iR jN-、羟基、R kS-、取代或未取代的磷酰基氧基、取代的甲酰基氧基，其中R i、R j独立地选自氢原子、C 1～C 6烷基或氨基保护基，R k选自氢原子、C 1～C 6烷基；
    更优选卤素、C 1～C 6烷基磺酰基氧基、全氟C 1～C 6烷基磺酰基氧基、芳基磺酰基氧基、芳烷基磺酰基氧基、杂芳基磺酰基氧基、R iR jN-、羟基、R kS-、取代或未取代的磷酰基氧基、取代的甲酰基氧基；
    Y选自氢原子和羧基保护基，优选氢原子、甲基、乙基、烯丙基、异戊烯基和三甲基硅基乙基。
  6. 根据权利要求1所述的制备方法，其特征在于，式II所示化合物为
    Figure PCTCN2019096504-appb-100004
    其中，LG为离去基团，优选卤素、取代的磺酰基氧基、R iR jN-、羟基、R kS-、取代或未取代的磷酰基氧基、取代的甲酰基氧基，其中R i、R j独立地选自氢原子、C 1～C 6烷基或氨基保护基，R k选自氢原子、C 1～C 6烷基；
    更优选卤素、C 1～C 6烷基磺酰基氧基、全氟C 1～C 6烷基磺酰基氧基、芳基磺酰 基氧基、芳烷基磺酰基氧基、杂芳基磺酰基氧基、R iR jN-、羟基、R kS-、取代或未取代的磷酰基氧基、取代的甲酰基氧基；
    Y选自氢原子和羧基保护基，优选氢原子、甲基、乙基、烯丙基、异戊烯基和三甲基硅基乙基。
  7. 根据权利要求1所述的制备方法，其特征在于，式III所示化合物为
    Figure PCTCN2019096504-appb-100005
    其中，R 1相同或不同，且各自独立地选自氢原子、卤素、烷基、卤代烷基、烷氧基、卤代烷氧基、氨基、硝基、氰基、羟基、羟烷基、环烷基、杂环基、芳基和杂芳基；
    R 5选自烷基、环烷基和卤代烷基，其中所述的烷基或环烷基任选进一步被选自氘原子、卤素、烷基和环烷基中的一个或多个取代基所取代；
    R 2、n的定义如权利要求1所述。
  8. 根据权利要求1所述的制备方法，其特征在于，式III所示化合物为
    Figure PCTCN2019096504-appb-100006
  9. 根据权利要求1所述的制备方法，其特征在于，式III所示化合物为
    Figure PCTCN2019096504-appb-100007
  10. 根据权利要求1所述的制备方法，其特征在于，所述制备方法还包括式IV所示化合物与式V所示化合物反应制备式II所示化合物的步骤，
    Figure PCTCN2019096504-appb-100008
    其中，R 11选自-OR 9、卤素；
    LG’与LG相同或不同，选自卤素、取代的磺酰基氧基、R iR jN-、羟基、R kS-、取代或未取代的磷酰基氧基、取代的甲酰基氧基，其中R i、R j独立地选自氢原子、C 1～C 6烷基或氨基保护基，R k选自氢原子、C 1～C 6烷基；
    L 1、R 3、R 4、R 9、LG、s的定义如权利要求1所述。
  11. 式IIb所示的化合物，
    Figure PCTCN2019096504-appb-100009
    其中，LG为离去基团，优选卤素、取代的磺酰基氧基、R iR jN-、羟基、R kS-、取代的甲酰基氧基，其中R i、R j独立地选自氢原子、C 1～C 6烷基或氨基保护基，R k选自氢原子、C 1～C 6烷基；
    更优选卤素、C 1～C 6烷基磺酰基氧基、全氟C 1～C 6烷基磺酰基氧基、芳基磺酰基氧基、芳烷基磺酰基氧基、杂芳基磺酰基氧基、R iR jN-、羟基、R kS-、取代的甲酰基氧基；
    Y选自氢原子和羧基保护基，优选氢原子、甲基、乙基、烯丙基、异戊烯基和三甲基硅基乙基；
    并且当LG为羟基时，Y不为甲基。
  12. 式IIc所示的化合物，
    Figure PCTCN2019096504-appb-100010
    其中，LG为离去基团，优选卤素、取代的磺酰基氧基、R iR jN-、羟基、R kS-、取代或未取代的磷酰基氧基、取代的甲酰基氧基，其中R i、R j独立地选自氢原子、C 1～C 6烷基或氨基保护基，R k选自氢原子、C 1～C 6烷基；
    更优选卤素、C 1～C 6烷基磺酰基氧基、全氟C 1～C 6烷基磺酰基氧基、芳基磺酰基氧基、芳烷基磺酰基氧基、杂芳基磺酰基氧基、R iR jN-、羟基、R kS-、取代的甲酰基氧基；
    Y选自氢原子和羧基保护基，优选氢原子、甲基、乙基、烯丙基、异戊烯基和三甲基硅基乙基。
  13. 一种如权利要求11所述的式IIb所示的化合物的制备方法，包括式IVb所示化合物或其盐与式Vb所示化合物或其盐反应的步骤，
    Figure PCTCN2019096504-appb-100011
    其中，R 11选自-OR 9、卤素；
    R 9选自氢原子、烷基、烷氧基、卤代烷基、卤代烷氧基、氨基、环烷基、杂环基、芳基和杂芳基；
    LG’与LG相同或不同，选自卤素、取代的磺酰基氧基、R iR jN-、羟基、R kS-、取代或未取代的磷酰基氧基、取代的甲酰基氧基，其中R i、R j独立地选自氢原子、C 1～C 6烷基或氨基保护基，R k选自氢原子、C 1～C 6烷基；
    LG、Y的定义如权利要求11所述。
  14. 一种如权利要求12所述的式IIc所示的化合物的制备方法，包括式IVc所示化合物或其盐与式Vb所示化合物或其盐反应的步骤，
    Figure PCTCN2019096504-appb-100012
    其中，R 11选自-OR 9、卤素；
    R 9选自氢原子、烷基、烷氧基、卤代烷基、卤代烷氧基、氨基、环烷基、杂环基、芳基和杂芳基；
    LG’与LG相同或不同，选自卤素、取代的磺酰基氧基、R iR jN-、羟基、R kS-、取代或未取代的磷酰基氧基、取代的甲酰基氧基，其中R i、R j独立地选自氢原子、C 1～C 6烷基或氨基保护基，R k选自氢原子、C 1～C 6烷基；
    LG、Y的定义如权利要求12所述。
  15. 一种式I所示化合物或其药学上可接受的盐的制备方法，包括式IIIb所示化合物与式IIb所示化合物反应制备式BI所示化合物的步骤，其中，LG、Y的定义如权利要求5所述，
    Figure PCTCN2019096504-appb-100013
  16. 根据权利要求15所述的制备方法，其特征在于，所述式IIIb所示化合物与式IIb所示化合物在碱性物质存在的条件下反应，所述碱性物质优选Na 2CO 3、K 2CO 3、Cs 2CO 3、NaHCO 3，KHCO 3、Na 2HPO 4、K 2HPO 4、K 3PO 4、Na 3PO 4、LiHMDS、NaHMDS、KHMDS、Ba(OH) 2、LiOR a、NaOR a、KOR a、CsOR a、TlOR a、NR bR cR d、DBU、DBN、Mg(OR a) 2，LiR e、NaNH 2、KNH 2、LiNH 2、LiH、NaH、KH、CaH 2、MgH 2、R fMgX、KF、CsF、Bu 4F、季铵盐中的一种或多种，其中R a独立地选自氢原子或C 1～C 6烷基，R b、R c、R d各独立地选自氢原子、烷基、环烷基，R e选自iBu，nBu，tBu，环己基，苯基，2,2,6,6-四甲基哌啶基，R f为C 1～C 6烷基，X为卤素，所述碱性物质更优选tBuOK、LiHMDS、NaHMDS、KHMDS、LiH、NaH、KH、CaH 2、MgH 2、TBAI、TBAF、TBAB、TBAC、Na 2CO 3、K 2CO 3、Cs 2CO 3、K 3PO 4、Na 3PO 4中的一种或多种。
  17. 根据权利要求15所述的制备方法，其特征在于，所述方法还包括权利要求13所述的制备式IIb所示的化合物的步骤。
  18. 根据权利要求15所述的制备方法，其特征在于，LG选自取代的磺酰基氧基，所述方法还包括式IId所示的化合物转化为式IIb所示的化合物的步骤，
    Figure PCTCN2019096504-appb-100014
  19. 根据权利要求15所述的制备方法，其特征在于，Y选自羧基保护基，所述方法还包括式BI所示化合物脱羧基保护基的步骤。
  20. 一种式VI所示化合物或其药学上可接受的盐的制备方法，包括式IIIc所示化合物与式IIc所示化合物反应制备式BVI所示化合物的步骤，其中，LG、Y的定义如权利要求5所述，
    Figure PCTCN2019096504-appb-100015
    Figure PCTCN2019096504-appb-100016
  21. 根据权利要求20所述的制备方法，其特征在于，所述式IIIc所示化合物与式IIc所示化合物在碱性物质存在的条件下反应，所述碱性物质优选Na 2CO 3、K 2CO 3、Cs 2CO 3、NaHCO 3，KHCO 3、Na 2HPO 4、K 2HPO 4、K 3PO 4、Na 3PO 4、LiHMDS、NaHMDS、KHMDS、Ba(OH) 2、LiOR a、NaOR a、KOR a、CsOR a、TlOR a、NR bR cR d、DBU、DBN、Mg(OR a) 2，LiR e、NaNH 2、KNH 2、LiNH 2、LiH、NaH、KH、CaH 2、MgH 2、R fMgX、KF、CsF、Bu 4F、季铵盐中的一种或多种，其中R a独立地选自氢原子或C 1～C 6烷基，R b、R c、R d各独立地选自氢原子、烷基、环烷基，R e选自iBu，nBu，tBu，环己基，苯基，2,2,6,6-四甲基哌啶基，R f为C 1～C 6烷基，X为卤素，所述碱性物质更优选tBuOK、LiHMDS、NaHMDS、KHMDS、LiH、NaH、KH、CaH 2、MgH 2、TBAI、TBAF、TBAB、TBAC、Na 2CO 3、K 2CO 3、Cs 2CO 3、K 3PO 4、Na 3PO 4中的一种或多种。
  22. 根据权利要求20所述的制备方法，其特征在于，所述方法还包括权利要求14所述的制备式IIc所示的化合物的步骤。
  23. 根据权利要求20所述的制备方法，其特征在于，LG选自取代的磺酰基氧基，所述方法还包括式IIe所示的化合物转化为式IIc所示的化合物的步骤，
    Figure PCTCN2019096504-appb-100017
  24. 根据权利要求20所述的制备方法，其特征在于，Y选自羧基保护基，所述方法还包括式BVI所示化合物脱羧基保护基的步骤。
  25. 式IVd所示的化合物，
    Figure PCTCN2019096504-appb-100018
    其中，Y 1选自氢原子或羧基保护基；Y 2选自氢原子或羟基保护基。
  26. 一种如权利要求25所述的式IVd所示的化合物的制备方法，包括式IVe所示的化合物转化为式IVd所示的化合物的步骤，
    Figure PCTCN2019096504-appb-100019
PCT/CN2019/096504 2018-07-19 2019-07-18 一种凝血因子XIa抑制剂及其中间体的制备方法 Ceased WO2020015698A1 (zh)

Priority Applications (10)

Application Number Priority Date Filing Date Title
CA3106120A CA3106120A1 (en) 2018-07-19 2019-07-18 Method for preparing coagulation factor xia inhibitor and intermediate thereof
CN201980004506.0A CN111094268B (zh) 2018-07-19 2019-07-18 一种凝血因子XIa抑制剂及其中间体的制备方法
BR112021000439-4A BR112021000439A2 (pt) 2018-07-19 2019-07-18 Método para preparar o inibidor do fator de coagulação xia e intermediário do mesmo
KR1020207037803A KR20210033953A (ko) 2018-07-19 2019-07-18 응고 인자 xia 억제제 및 이의 중간체의 제조 방법
AU2019304392A AU2019304392A1 (en) 2018-07-19 2019-07-18 Method for preparing coagulation factor XIa inhibitor and intermediate thereof
JP2021500812A JP2021530497A (ja) 2018-07-19 2019-07-18 凝固第ＸＩａ因子阻害剤およびその中間体の調製方法
MX2021000256A MX2021000256A (es) 2018-07-19 2019-07-18 Metodo de preparacion de inhibidor del factor de coagulacion xia e intermediario del mismo.
EP19837834.1A EP3825311A4 (en) 2018-07-19 2019-07-18 METHOD OF PREPARING A COAGAGING FACTOR XIA INHIBITOR AND INTERMEDIATE THEREOF
US17/259,917 US20210292279A1 (en) 2018-07-19 2019-07-18 Method for preparing coagulation factor xia inhibitor and intermediate thereof
ZA2020/07755A ZA202007755B (en) 2018-07-19 2020-12-11 Method for preparing coagulation factor xia inhibitor and intermediate thereof

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN201810796646 2018-07-19
CN201810796646.3 2018-07-19

Publications (1)

Publication Number Publication Date
WO2020015698A1 true WO2020015698A1 (zh) 2020-01-23

Family

ID=69163576

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CN2019/096504 Ceased WO2020015698A1 (zh) 2018-07-19 2019-07-18 一种凝血因子XIa抑制剂及其中间体的制备方法

Country Status (12)

Country Link
US (1) US20210292279A1 (zh)
EP (1) EP3825311A4 (zh)
JP (1) JP2021530497A (zh)
KR (1) KR20210033953A (zh)
CN (1) CN111094268B (zh)
AU (1) AU2019304392A1 (zh)
BR (1) BR112021000439A2 (zh)
CA (1) CA3106120A1 (zh)
MX (1) MX2021000256A (zh)
TW (1) TW202019904A (zh)
WO (1) WO2020015698A1 (zh)
ZA (1) ZA202007755B (zh)

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116262740A (zh) * 2022-11-18 2023-06-16 成都施贝康生物医药科技有限公司 新型氧代吡啶类化合物及其制备方法和用途
CN116262734A (zh) * 2022-11-18 2023-06-16 成都施贝康生物医药科技有限公司 新型氧代吡啶类化合物及其制备方法和用途
CN116621728A (zh) * 2023-06-09 2023-08-22 成都施贝康生物医药科技有限公司 氧代吡啶类化合物的新型制备方法及关键中间体
CN116621742A (zh) * 2023-06-09 2023-08-22 成都施贝康生物医药科技有限公司 氧代吡啶类化合物的新型制备方法及关键中间体
CN116730861A (zh) * 2023-06-21 2023-09-12 成都施贝康生物医药科技有限公司 氧代吡啶类化合物的新型制备方法及关键中间体
CN116751136A (zh) * 2023-06-21 2023-09-15 成都施贝康生物医药科技有限公司 氧代吡啶类化合物的新型制备方法及关键中间体
CN116874387A (zh) * 2023-06-21 2023-10-13 成都施贝康生物医药科技有限公司 氧代吡啶类化合物的新型制备方法及关键中间体

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020007256A1 (zh) * 2018-07-02 2020-01-09 江苏恒瑞医药股份有限公司 一种氧代吡啶酰胺类衍生物的晶型及制备方法
CN112010774B (zh) * 2019-05-28 2024-03-08 上海美悦生物科技发展有限公司 FXIa凝血因子抑制剂、其药物组合物和用途

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1944398A (zh) * 2005-01-11 2007-04-11 中国医学科学院药物研究所 新的苯甲酰胺类化合物及其制法和药物用途
WO2016046156A1 (de) * 2014-09-24 2016-03-31 Bayer Pharma Aktiengesellschaft Substituierte oxopyridin-derivate
WO2018041122A1 (zh) 2016-08-31 2018-03-08 江苏恒瑞医药股份有限公司 氧代吡啶酰胺类衍生物、其制备方法及其在医药上的应用
CN107793396A (zh) * 2016-08-31 2018-03-13 江苏恒瑞医药股份有限公司 环氧基取代的氧代吡啶类衍生物、其制备方法及其在医药上的应用

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7378409B2 (en) * 2003-08-21 2008-05-27 Bristol-Myers Squibb Company Substituted cycloalkylamine derivatives as modulators of chemokine receptor activity
FR3005160B1 (fr) * 2013-04-29 2016-02-12 Sagem Defense Securite Capteur angulaire inertiel de type mems equilibre et procede d'equilibrage d'un tel capteur
US9676723B2 (en) * 2014-02-11 2017-06-13 Merck Sharp & Dohme Corp Factor XIa inhibitors
CN107428689A (zh) * 2015-03-19 2017-12-01 拜耳制药股份公司 作为治疗血栓形成的因子xia抑制剂的氧代吡啶衍生物
KR20180069782A (ko) * 2015-08-03 2018-06-25 프레지던트 앤드 펠로우즈 오브 하바드 칼리지 하전 이온 채널 블록커 및 이용 방법
CN108137549B (zh) * 2015-08-05 2021-07-20 百时美施贵宝公司 取代的甘氨酸衍生的fxia抑制剂
US20180250280A1 (en) * 2015-09-04 2018-09-06 Bayer Pharma Aktiengesellschaft Substituted oxopyridine derivatives
CN107033043B (zh) * 2016-02-04 2019-04-30 中国人民解放军第二军医大学 N-取代苯磺酰基-取代苯甲酰胺类化合物及其制备药物的用途
IT201600074606A1 (it) * 2016-07-18 2018-01-18 Italfarmaco Spa New benzo-N-hydroxy amide compounds having antitumor activity
TWI592671B (zh) * 2016-08-04 2017-07-21 台達電子工業股份有限公司 絕緣偵測電路、電源轉換裝置及絕緣阻抗值偵測方法
EP3532469A1 (en) * 2016-10-26 2019-09-04 Proteostasis Therapeutics, Inc. Compounds, compositions, and methods for modulating cftr

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1944398A (zh) * 2005-01-11 2007-04-11 中国医学科学院药物研究所 新的苯甲酰胺类化合物及其制法和药物用途
WO2016046156A1 (de) * 2014-09-24 2016-03-31 Bayer Pharma Aktiengesellschaft Substituierte oxopyridin-derivate
WO2018041122A1 (zh) 2016-08-31 2018-03-08 江苏恒瑞医药股份有限公司 氧代吡啶酰胺类衍生物、其制备方法及其在医药上的应用
CN107793396A (zh) * 2016-08-31 2018-03-13 江苏恒瑞医药股份有限公司 环氧基取代的氧代吡啶类衍生物、其制备方法及其在医药上的应用

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
See also references of EP3825311A4
T. W. GREENEP. G M. WUTS: "Protective Groups in Organic Synthesis"

Cited By (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116262740A (zh) * 2022-11-18 2023-06-16 成都施贝康生物医药科技有限公司 新型氧代吡啶类化合物及其制备方法和用途
CN116262734A (zh) * 2022-11-18 2023-06-16 成都施贝康生物医药科技有限公司 新型氧代吡啶类化合物及其制备方法和用途
CN116262734B (zh) * 2022-11-18 2025-05-13 成都施贝康生物医药科技有限公司 氧代吡啶类化合物及其制备方法和用途
CN116621728A (zh) * 2023-06-09 2023-08-22 成都施贝康生物医药科技有限公司 氧代吡啶类化合物的新型制备方法及关键中间体
CN116621742A (zh) * 2023-06-09 2023-08-22 成都施贝康生物医药科技有限公司 氧代吡啶类化合物的新型制备方法及关键中间体
CN116621728B (zh) * 2023-06-09 2025-07-29 成都施贝康生物医药科技有限公司 氧代吡啶类化合物的新型制备方法及关键中间体
CN116730861A (zh) * 2023-06-21 2023-09-12 成都施贝康生物医药科技有限公司 氧代吡啶类化合物的新型制备方法及关键中间体
CN116751136A (zh) * 2023-06-21 2023-09-15 成都施贝康生物医药科技有限公司 氧代吡啶类化合物的新型制备方法及关键中间体
CN116874387A (zh) * 2023-06-21 2023-10-13 成都施贝康生物医药科技有限公司 氧代吡啶类化合物的新型制备方法及关键中间体

Also Published As

Publication number Publication date
EP3825311A1 (en) 2021-05-26
BR112021000439A2 (pt) 2021-04-06
EP3825311A4 (en) 2022-08-31
MX2021000256A (es) 2021-03-25
AU2019304392A1 (en) 2021-01-28
CN111094268B (zh) 2022-07-26
CN111094268A (zh) 2020-05-01
US20210292279A1 (en) 2021-09-23
JP2021530497A (ja) 2021-11-11
TW202019904A (zh) 2020-06-01
ZA202007755B (en) 2022-06-29
KR20210033953A (ko) 2021-03-29
CA3106120A1 (en) 2020-01-23

Similar Documents

Publication Publication Date Title
WO2020015698A1 (zh) 一种凝血因子XIa抑制剂及其中间体的制备方法
CN120344540A (zh) Kras-protac嵌合化合物及其制备方法和用途
JP7212142B2 (ja) Ｈｐｋ１阻害剤およびその調製方法と応用
ES2380443T3 (es) Proceso para la producción de ácido 1-(3-(2-(1-benzotiofen-5-il)etoxi)propiónico o sales del mismo
WO2014036897A1 (zh) 咪唑啉类衍生物、其制备方法及其在医药上的应用
WO2018086591A1 (zh) 吡啶胺取代的杂三环化合物、其制法与医药上的用途
CN116964058A (zh) Kras g12d抑制剂及其在医药上的应用
JP2025516367A (ja) Ｐａｒｐ１を選択的に阻害するフルオロキノキサリノン誘導体
CA3104956C (en) Novel lxr modulators with bicyclic core moiety
BRPI0714885A2 (pt) compostos terapÊuticos
JP7419575B2 (ja) 縮合環インダゾール系化合物
TW202220976A (zh) Cd73抑制劑及其在醫藥上的應用
EP4132908A1 (en) Indole derivatives as alpha-1 -antitrypsin modulators for treating alpha-1 -antitrypsin deficiency (aatd)
AU2019391942B2 (en) Macrocyclic compound and use thereof
WO2021057998A1 (zh) 一种吡咯并氨基哒嗪酮化合物的制备方法
TW201925211A (zh) 用於製備苯并噻吩-2-基硼酸酯之方法
IL298275A (en) 3-((1h-pyrazol-4-yl)methyl)-6'-(phenyl)-2h-(2,1'-bipyridine)-2-one derivatives and related compounds as gpr139 antagonists for use in a method of treating, for example, depression
CN103524466A (zh) 二氢苯并呋喃类衍生物、其制备方法、中间体及其应用
RU2779013C2 (ru) Способ получения ингибитора фактора свертывания крови xia и его интермедиата
WO2018086590A1 (zh) 砜基取代的苯并杂环衍生物、其制法与医药上的用途
TW202330514A (zh) 三並環衍生物及其製備方法和應用
CN103958484B (zh) 噁唑烷酮类衍生物、其制备方法及其在医药上的应用
CN114702443A (zh) 喹诺酮类化合物及其中间体的制备方法
CA3191456A1 (en) Novel compounds having inhibitory activity on prostaglandin e2 receptor and uses thereof
KR870000289B1 (ko) 2-옥스인돌 유도체의 제조방법

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 19837834

Country of ref document: EP

Kind code of ref document: A1

ENP Entry into the national phase

Ref document number: 3106120

Country of ref document: CA

ENP Entry into the national phase

Ref document number: 2021500812

Country of ref document: JP

Kind code of ref document: A

REG Reference to national code

Ref country code: BR

Ref legal event code: B01A

Ref document number: 112021000439

Country of ref document: BR

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 2019304392

Country of ref document: AU

Date of ref document: 20190718

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 2019837834

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 112021000439

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20210111